

09/02/98 15573 U.S. PRO

Please type a plus sign (+) inside this box → +

PTO/SB/05 (1/98)
Approved for use through 9/30/2000. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	A52023.1
First Inventor or Application	Madiyalakan, et al.
Title	Therapeutic Compositions that Produce an Immune Response
Express Mail Label No.	

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application	ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, D.C. 20231
1. <input type="checkbox"/> *Fee Transmittal Form (e.g., PTO/SB/17)	6. <input type="checkbox"/> Microfiche Computer Program (Appendix)
2. <input checked="" type="checkbox"/> Specification [Total 84] - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure	7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. <input type="checkbox"/> Computer Readable Copy b. <input type="checkbox"/> Paper Copy (identical to computer copy) c. <input type="checkbox"/> Statement verifying identity of above copies
3. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total 19]	
4. Oath or Declaration [Total] a. <input type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 C.F.R. 1.63(d)) [Note Box 5 below] i. <input type="checkbox"/> DELETION OF INVENTOR(S) inventor(s) named in the prior application.	
5. <input type="checkbox"/> Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is	

ACCOMPANYING APPLICATION PARTS
8. ☐ Assignment Papers (cover sheet &
9. ☐ 37 C.F.R. 3.73(b) Statement ☐ Power of Attorney
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
14. ☐ * Small Entity Statement(s) ☐ Statement filed in prior application, (PTO/SB/09-12)
15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. ☐ Other: _____
* A new statement is required to be entitled to pay small entity fees, except

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:
☐ Continuation ☐ Divisional ☒ Continuation-in-part (CIP) of prior application 09/094,598
Prior application information: Examiner _____ Group / Art Unit 1654

18. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label here) or ☒ Correspondence address below

Name	William J. Bundren				
Address	576 Farmington Raod, West				
City	Accokeek	State	MD	Zip Code	20607-9796
Country	US	Telephone	301-203-9781	Fax	301-203-9825

Name (Print/Type)	William J. Bundren	Registration No. (Attorney/Agent)	31,712
Signature	<i>William J. Bundren</i>	Date	2 September 1998

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

1

THERAPEUTIC COMPOSITIONS THAT PRODUCE AN IMMUNE RESPONSE

6

This application is a continuation-in-part of International Application No. PCT/IB96/00461, filed May 15, 1996; a continuation-in-part of U.S. Serial No. 08/877,302, filed June 16, 1997; a continuation-in-part of U.S. Serial No. 08/782,048, filed January 10, 1997; a continuation-in-part of U.S. Serial No. 08/877,511, filed June 17, 1997; and a continuation-in-part of U.S. Serial No. 09/094,598, filed June 15, 1998.

Technical Field

11

The invention concerns methods and compositions having increased therapeutic effect by altering the immunogenicity of the active component without decreasing the active component's antigenicity. For some embodiments of the invention, e.g., cancer immunotherapy, immunogenicity is increased. The invention also concerns methods and compositions for stimulating a host's immune response, particularly for the treatment of cancer. The methods and compositions according to the invention use binding agents such as antibodies to generate an immune response to a pre-determined antigen.

16

Background Art

21

In vertebrates, the mechanisms of natural and specific immunity cooperate within a system of host defenses, the immune system, to eliminate foreign invaders. In addition to microbes, cancer cells, parasites and virus-infected cells, the immune system also recognizes and eliminates cells or tissues transplanted into a subject from a genetically different individual of the same species (allografts) or from a different species (xenografts).

1 Treatment for cancer has traditionally encompassed three main strategies:
surgery, chemotherapy, and radiotherapy. Although considerable progress in these
areas has been attained, the search for more effective and safe alternative treatments
continues.

6 The hypothesis that the immune system ought to be able to recognize
tumors and thus could be recruited in the fight against cancer has been a driving
force behind outstanding efforts of many immunologists. This approach is attractive
because of the unique ability of the immune system to specifically destroy affected
cells while mostly sparing normal tissue. Moreover, the initial immune response is
known to leave behind a long-term memory that serves to protect from the same
11 disease in the future. No drug treatment for cancer can claim such specificity or
memory.

16 An immunotherapeutic strategy for the treatment of cancer and other
diseases involve one or more components of the immune system to trigger a
complex cascade of biological reactions focused on eliminating a foreign molecule
from the host. Vertebrates have two broad classes of immune responses: antibody
responses, or humoral immunity, and cell-mediated immune responses, or cellular
immunity.

Humoral Immunity

21 Humoral immunity is provided by B lymphocytes, which, after
proliferation and differentiation, produce antibodies (proteins also known as
immunoglobulins) that circulate in the blood and lymphatic fluid. These antibodies
specifically bind to the antigen that induced them. Binding by antibody inactivates
the foreign substance, e.g., a virus, by blocking the substance's ability to bind to
receptors on a target cell or by attracting complement or the killer cells that attack
26 the virus. The humoral response primarily defends against the extracellular phases
of bacterial and viral infections. In humoral immunity, serum alone can transfer the

1 response, and the effectors of the response are protein molecules, typically soluble,
called antibodies. Lymphocytes determine the specificity of immunity, and it is
their response that orchestrates the effector limbs of the immune system. Cells and
proteins, such as antibodies, that interact with lymphocytes play critical roles in
both the presentation of antigen and in the mediation of immunologic functions.

6 Individual lymphocytes respond to a limited set of structurally related
antigens. As noted in more detail below, this function is defined structurally by the
presence of receptors on the lymphocyte's surface membrane that are specific for
binding sites (determinants or epitopes) on the antigen.

11 Lymphocytes differ from each other not only in the specificity of their
receptors, but also in their functions. One class of lymphocytes, B cells, are
precursors of antibody-secreting cells, and function as mediators of the humoral
immune response. Another class of lymphocytes, T cells, express important
regulatory functions, and are mediators of the cellular immune response.

Cellular Immunity

16 The second class of immune responses, cellular immunity, involve the
production of specialized cells, e.g., T lymphocytes, that react with foreign antigens
on the surface of other host cells. The cellular immune response is particularly
effective against fungi, parasites, intracellular viral infections, cancer cells and other
foreign matter. In fact, the majority of T lymphocytes play a regulatory role in
21 immunity, acting either to enhance or suppress the responses of other white blood
cells. These cells, called helper T cells and suppressor T cells, respectively, are
collectively referred to as regulatory cells. Other T lymphocytes, called cytotoxic T
cells, kill virus-infected cells. Both cytotoxic T cells and B lymphocytes are
involved directly in defense against infection and are collectively referred to as
26 effector cells.

The time course of an immune response is subdivided into the cognitive or

1 recognition phase, during which specific lymphocytes recognize the foreign antigen;
the activation phase, during which specific lymphocytes respond to the foreign
antigen; and the effector phase, during which antigen-activated lymphocytes mediate
the processes required to eliminate the antigen. Lymphocytes are immune cells that
are specialized in mediating and directing specific immune responses. T cells and B
6 cells become morphologically distinguishable only after they have been stimulated
by an antigen.

In addition to a humoral response, the immune system may also generate a
cellular response mediated by activated T-cells. There are a number of intercellular
signals important to T cell activation. Under normal circumstances an antigen
11 degrades or is cleaved to form antigen fragments or peptides. Presentation of
antigen fragments to T-cells is the principal function of MHC molecules, and the
cells that carry out this function are called antigen-presenting cells (APC: including
but not limited to dendritic cells, macrophages, and B cells).

The capture and processing of an antigen by APCs is essential for the
induction of a specific immune response. The three major APCs are dendritic cells,
macrophages and B-lymphocytes; dendritic cells are the most efficient. The injected
antibody can form a complex with a circulating antigen (e.g., PSA or Ca 125), these
immune complexes can be targeted to dendritic cells and macrophages through the
Fc-receptors present on these cells. However the high number of Fc receptors on
neutrophils may considerably limit this process.
16
21

Cancer immunotherapy is based on the principle of inducing or activating
the immune system to recognize and eliminate neoplastic cells. The key elements in
any immunotherapy is to induce or trigger the host immune system to first
recognize a molecule as an unwanted target, and then to induce the system to
initiate a response against that molecule. In healthy hosts, the immune system
26 recognizes surface features of a molecule that is not a normal constituent of the host
(i.e., is "foreign" to the host). Once the recognition function occurs, the host must

then direct a response against that particular foreign molecule.

Both the recognition and the response elements of the immune system involve a highly complex cascade of biological reactions. In most immunologically based disorders, at least one of the steps in the recognition phase, or at least one of the steps in the response phase, are disrupted. Virtually any disruption in either of these complex pathways leads to a reduced response or to the lack of any response. The inability of the immune system to destroy a growing tumor has been attributed, among other factors, to the presence of tumor-associated antigens (TAA) that induce immunological tolerance and/or immunosuppression. For example, in some kinds of cancer, the cancer itself tricks the host into accepting the foreign cancer cell as a normal constituent, thus disrupting the recognition phase of the immune system. The immunological approach to cancer therapy involves modification of the host-tumor relationship so that the immune system is induced or amplifies its response to the TAAs. If successful, inducing or amplifying the immune system can lead to tumor regression, tumor rejection, and occasionally, to tumor cure.

Antigenicity and Immunogenicity

As used herein, if a binding agent can be recognized by an antigen, i.e., can bind to or interact with an antigen, then the binding agent is said to be antigenic. If the immune system can also mount an active response against the binding agent, a complex containing the binding agent, a portion of the complex, or the antigen, it is said to be immunogenic.

The conventional definition of an antigen is a substance that can elicit in a vertebrate host the formation of a specific antibody or the generation of a specific population of lymphocytes reactive with the substance. As frequently occurs in science, however, it is now known that this definition, although accurate, is not complete. For example, it is now known that some disease conditions suppress or

1 inactivate the host immune response, and the substance that would have been
expected to elicit an antibody or generate specific lymphocytes, does not. Thus, not
all antigens are capable of eliciting a human immune response.

Typically, the antibody's capability of binding the antigen is based on highly
complementary structures. That is, the shape of the antibody must contain
6 structures that are the compliment of the structures on the antigen. The portion of
the antigen to which an antibody binds is called the "antigenic determinant", or
"epitope". Thus antigens are molecules that bear one or more epitopes which may
be recognized by specific receptors in an immune system, a property called
antigenicity.

11 Antigens are molecules that interact with specific lymphocyte receptors –
surface T cell antigen receptors and B cell immunoglobulin receptors. A particular
B or T cell binds to a very specific region of the antigen, called an antigenic
determinant or epitope.

Immunogenicity refers to the property of stimulating the immune system to
generate a specific response. Thus, all immunogens are antigens, but not vice-versa.
16 Although an immune system may recognize an antigen (e.g., binds to a T or B cell
receptor), it does not respond to the antigen unless the antigen or an antigen-
containing complex is also immunogenic.

An immune response to a particular antigen is greatly influenced by the
structure and activity of the antigen itself, as well as myriad other factors. In some
cases, the immune system is not able to generate an immune response to a particular
antigen, a condition that is called tolerance.

In influencing whether an antigen is immunogenic or immunotolerant, an
important characteristic of the antigen is the degree of difference between the
26 antigen and similar molecules within the host. The most immunogenic antigens are
those that have no homologs in the host, i.e., those that are most "foreign." Other
factors that promote immunogenicity include higher molecular weight, greater

1 molecular complexity, the proper antigen dose range, the route of administration,
the age of the host, and the genetic composition of the host (including exposure to
antigens during fetal development).

6 As noted above, antigens may have one or more epitopes or binding sites
that are recognized by specific receptors of the immune system. Epitopes may be
formed by the primary structure of a molecule (called a sequential epitope), or may
be formed by portions of the molecule separate from the primary structure that
juxtapose in the secondary or tertiary structure of the molecule (called a
conformational epitope). Some epitopes are hidden in the three dimensional
structure of the native antigen, and become immunogenic only after a
11 conformational change in the antigen provides access to the epitope by the specific
receptors of the immune system. Some antigens, e.g., tumor-associated antigens
such as ovarian cancer or breast cancer antigens, have multiple antibody binding
sites. These antigens are termed "multi-epitopic" antigens.

16 An important feature and function of a comprehensive therapeutic reagent is
the ability to initiate recognition and response to an antigen, to induce a cellular and
humoral response (either or both) to the antigen, and to increase the
immunogenicity of a molecule without affecting its antigenicity.

21 To cope with the immense variety of epitopes encountered, the immune
system of a mammalian individual contains an extremely large repertoire of
lymphocytes, approximately 2×10^{12} . Each lymphocyte clone of the repertoire
contains surface receptors specific for one epitope. It is estimated that the
mammalian immune system can distinguish at least 10^8 distinct antigenic
determinants. Even a single antigenic determinant will, in general, activate many
clones, each of which produces an antigen-binding site with its own characteristic
26 affinity for the determinant.

Antibodies, also known as immunoglobulins, are proteins. They have two
principal functions. The first is to recognize (bind) antigens. The second is to

1 mobilize other elements of the immune system to destroy the foreign entity. An
antibody binds to an epitope of an antigen as a result of molecular complementarity.
The portions of the antibody which participate directly in the interaction is called
"antigen binding site", or "paratope". The antigens bound by a particular antibody
are called its "cognate antigens".

6 Antibodies bear three major categories of antigen-specific determinants –
isotypic, allotypic, and idiotypic – each of which is defined by its location on the
antibody molecule. For the purpose of the present invention, we shall only focus
on the idiotypic category.

11 Idiotypic determinants, or idiotopes, are markers for the V region of an
antibody, a relatively large region that may include several idiotopes each capable of
interacting with a different antibody. The set of idiotopes expressed on a single
antibody V region constitutes the antibody idio type. An antibody (Ab1) whose
antigen combining site (paratope) interacts with an antigenic determinant on
another antibody V region (idiotope) is called an anti-idiotypic antibody (Ab2).
16 Thus, an Ab2 antibody includes an antigen binding site, and may include one or
more antibody binding sites.

21 The idio type of an antibody is defined by individually distinctive antigenic
determinants in the variable or idiotypic region of the antibody molecule. A
portion of these idiotypic determinants will be on or closely associated with the
paratope of the antibody, while others will be in the framework of the variable
region. While each antibody has its own idio type, particular antibodies will be
referred to below by the following terms. "Idio type antibody" or "Id Ab" refers to
an anti-antibody (i.e., the epitope identified by the idio type antibody is on a cell or a
soluble antigen, such as a tumor associated antigen). "Anti-idio type antibody" or
26 "anti-Id Ab" refers to an antibody which identifies an epitope in the variable region
of an idio type antibody. A portion of such antibodies will identify an epitope
within the paratope of the idio type antibody, thus presenting an "internal" image of

1 the epitope identified by the idiotype antibody on the tumor associated antigen.
"Anti-(anti-idiotype) antibody" or "anti-(anti-Id) Ab" is an antibody that identifies
an epitope in the variable region of the anti-idiotype antibodies. A portion of the
anti-(anti-idiotype) antibodies will identify an epitope that corresponds to (i) the
paratope of the anti-idiotype antibody, and (ii) an epitope on a tumor associated
6 antigen.

There are four types of anti-idiotypic antibodies, sometimes called Ab2 α ,
Ab2 β , Ab2 γ , and Ab2 δ . In one type of anti-idiotype antibody (Ab2 β), the
combining site perfectly mimics the structure of the antigen epitope recognized by
the Ab1 antibody (i.e., whose paratope always mimics the epitope of the original
11 antigen). This type of anti-idiotype is said to represent the internal image of the
antigen. By definition, the antigen and this type of anti-idiotype antibody compete
for the same binding site on Ab1, and the antigen inhibits the interaction between
Ab1 and the anti-idiotypic antibody. The phenomenon of producing an anti-
idiotypic antibody having the internal image of the antigen may permit the use of
16 antibodies to replace the antigen as an immunogen.

The second type of anti-idiotype, Ab2 α , binds an epitope remote from the
paratope of the primary antibody (binds to an idiotope of Ab1 that is distinct from
the antigen binding site), and therefore may be characterized in terms of the
antigen's inability to prevent the binding of the anti-idiotype to Ab1. For this type
of anti-idiotype, Ab1 can bind to both the antigen and the anti-idiotypic antibody.
21 For a graphic representation of these types of antibodies and their interaction, see
Figure 1.

The third type, Ab2 γ , binds near enough to the paratope of the primary
antibody to interfere with antigen binding. The fourth type, Ab2 δ , recognizes an
26 idiotypic determinant that mimics a constant domain antigenic structure.

Anti-idiotypic antibodies often have immunological characteristics similar to
those of an antigen cognate to the immunizing antibody. Anti-isotypic antibodies,

on the other hand, bind epitopes in the constant region of the immunizing antigen.

For tumors that have antigens, there are at least four theories why the immune response may fail to destroy a tumor: 1) there are no B cells or cytotoxic T lymphocytes (CTL) capable of recognizing the tumor; 2) there are no TH cells capable of recognizing the tumor; 3) TS cells become activated before TH cells, thus preventing B-cell and CTL activation; and 4) the genes regulating tumor proliferation may be present from birth, so the host does not treat the gene products as "foreign."


"Passive immunotherapy" involves the administration of antibodies to a patient. Antibody therapy is conventionally characterized as passive since the patient is not the source of the antibodies. However, the term passive is misleading because the patient can produce anti-idiotypic secondary antibodies which in turn can provoke an immune response which is cross-reactive with the original antigen. "Active immunotherapy" is the administration of an antigen, in the form of a vaccine, to a patient, so as to elicit a protective immune response. Genetically modified tumor cell vaccines transfected with genes expressing cytokines and co-stimulatory molecules have also been used to alleviate the inadequacy of the tumor specific immune response.

If a specific antibody from one animal is injected as an immunogen into a suitable second animal, the injected antibody will elicit an immune response (e.g., produce antibodies against the injected antibodies -- "anti-antibodies"). Some of these anti-antibodies will be specific for the unique epitopes (idiotopes) of the variable domain of the injected antibodies. These epitopes are known collectively as the idiotype of the primary antibody; the secondary (anti-) antibodies which bind to these epitopes are known as anti-idiotypic antibodies. The sum of all idiotopes present on the variable portion of an antibody is referred to as its idiotype. Idiotypes are serologically defined, since injection of a primary antibody that binds an epitope of the antigen may induce the production of anti-idiotypic antibodies.

When binding between the primary antibody and an anti-idiotypic antibody is inhibited by the antigen to which the primary antibody is directed, the idiotype is binding site or epitope related. Other secondary antibodies will be specific for the epitopes of the constant domains of the injected antibodies and hence are known as anti-isotypic antibodies. As used herein, anti-idiotypic, anti-idiotypic antibody, epitope, or epitopic are used in their art-recognized sense.

The various interactions based on idiotypic determinants, called the idiotypic network, is based on the immunogenicity of the variable regions of immunoglobulin molecules (Ab1) which stimulate the immune system to generate anti-idiotypic antibodies (Ab2), some of which mimic antigenic epitopes ("internal image") of the original antigen. The presence of internal image antibodies (Ab2) in the circulation can in turn induce the production of anti-anti-idiotypic antibodies (Ab3), some of which include structures that react with the original antigen.

The "network" theory states that antibodies produced initially during an immune response will carry unique new epitopes to which the organism is not tolerant, and therefore will elicit production of secondary antibodies (Ab2) directed against the idiotypes of the primary antibodies (Ab1). These secondary antibodies likewise will have an idiotype which will induce production of tertiary antibodies (Ab3) and so forth.



The network theory also suggests that some of these secondary antibodies (Ab2) will have a binding site that is the complement of the original antigen and thus will reproduce the "internal image" of the original antigen. In other words, an anti-idiotypic antibody may be a surrogate antigen.

Two therapeutic applications arose from the network theory: 1) administer Ab1 which acts as an antigen inducing Ab2 production by the host; and 2)

1 administer Ab2 which functionally imitates the tumor antigen.

• The development of the "network" theory led investigators to suggest the direct administration of exogenously produced anti-idiotypic antibodies, that is, antibodies raised against the idiotype of an anti-tumor antibody. Such an approach is disclosed in U.S. Patent 5,053,224 (Koprowski, et al.) Koprowski assumes that the patient's body will produce anti-antibodies that will not only recognize these anti-idiotypic antibodies, but also the original tumor epitope.

Conventional anti-idiotypic antibodies are made by intraspecies or interspecies immunization with a purified antigen-specific pool of antibodies or a monoclonal antibody. The resulting antiserum is then extensively absorbed against similar molecules with the same constant region to remove antibodies with anti- C_HC_L specificities. See, for example, Briles, et al.; "Idiotypic Antibodies," *Immunochemical Techniques* (New York, Academic; Colowich and Kaplan, eds; 1985). The production of anti-ID antibodies against self-idiotopes was one of the first key predictions of the network theory [Rodkey, S., *J. Exp. Med* 130:712-719 (1974)].

A human anti-idiotypic monoclonal antibody (Ab2) has been shown to induce anti-tumor cellular responses in animals and appears to prolong survival in patients with metastatic colorectal cancer. See Durrant, L.G. et al., "Enhanced Cell-Mediated Tumor Killing in Patients Immunized with Human Monoclonal Anti-Idiotypic Antibody 105AD7," *Cancer Research*, 54:4837-4840 (1994). The use of anti-idiotypic antibodies (Ab2) for immunotherapy of cancer is also reviewed by Bhattacharya-Chatterje, et al; *Cancer Immunol. Immunother.* 38:75-82 (1994).

Idiotopes on lymphoid receptors may in some cases mimic external antigens because of the extensive diversity of the immune system. This idea prompted many attempts to use the internal image of a foreign antigen, mimicked by the idiotypes of T or B receptors, to act as targets for anti-idiotypic antibodies. In this way, it has been proposed that anti-idiotypic antibodies may induce populations of T or B

cells that can bind the extrinsic (or soluble) antigen. Such anti-idiotypic antibodies can be used as vaccines, many of which are summarized in Greenspan, NS, and Bona, CA; *The FASEB Journal*, 7:437-444 (1992).

The ability to up- or down-regulate immune responses and to control potentially auto-reactive immunocompetent cells is vital for normal immune function and survival. Regulatory mechanisms include the induction of clonal anergy (via inappropriate antigen-presenting cells), peripheral clonal deletion/apoptosis, cytokine (e.g. transforming growth factor-beta (TGF- β) or IL-10)-induced non-responsiveness, 'veto' cells, auto-reactive cytolytic T cells, and both non-specific and antigen-specific T suppressor cells. At least in theory, each of these regulatory systems provides a mechanistic basis for 'therapeutic intervention'.

In addition to cancer immunotherapy, control of abnormal acute and chronic inflammatory response is also one of the most important challenges in medicine. Typical examples of acute and chronic inflammation include atopy, urticaria, asthma, autoimmune hemolytic anemia, rheumatoid arthritis, systemic lupus erythematosus, granulomatous diseases, tuberculosis, and leprosy.

Like the tumor immune response described above, the aim of the inflammatory response is the elimination of harmful agents. Further, the treatment of autoimmune inflammatory disease is sometimes complicated by autoimmune factors that prevent the host from eliminating the harmful agents, thereby leading to a persistent or chronic inflammatory response or condition.

Presently, it has been determined that essential events in the development of inflammation includes a cellular response involving neutrophils and macrophages, specifically the rolling, activation, and adhesion of neutrophils to endothelium via selectins-carbohydrate ligand interaction (and may include neutrophil extravasation).

Therapeutic compositions for the treatment of inflammation have included agents that bind to one or more of the mediators of inflammation. For example,

1 antibodies specific for selectin carbohydrate ligands, and inhibiting selectin-
carbohydrate ligand binding, may be important anti-inflammatory targets for the
development of therapeutic compositions for the treatment of inflammation.

6 In addition to the above, there are other cases where an anti-idiotypic mode
of induction of a response may be useful. If a given epitope of a protein is
discontinuous and results from three-dimensional folding, an anti-Id can be
produced that would mimic that structure. Further, in immunizing against latent
and/or immunosuppressive viruses, there is the possibility of well known
deleterious effects not solvable by the use of attenuated viruses (e.g., mumps,
measles, rubella, and HIV). The use of anti-ID induction of protective immunity
11 may avoid these deleterious effects.

Summary of the Invention

16 The present invention is a method and composition for generating both a
humoral and/or a cellular immune response by administering a binding agent that
specifically binds to a pre-selected soluble antigen. In accordance with the
invention, the binding agent alone and/or the binding agent-soluble antigen
complex, either acting as an immunogen, alters the immunogenic condition of the
host. The binding agent or the binding agent/antigen complex generate new
immunogens that are recognizable by the immune system. This leads to a humoral
and/or a cellular response, which may include an anti-tumor response and/or cell
21 killing.

26 The present invention is a comprehensive method for the treatment of
certain diseases and conditions that includes, but is not limited to, targeting a
soluble antigen, preferably a multi-epitopic antigen; and administering a binding
agent, preferably a monoclonal antibody. In a preferred embodiment of the
invention, the binding agent or the binding agent/antigen complex induces the
production of a humoral response, as evidenced in part by the production of anti-

1 tumor or anti-inflammation antibodies, Ab3 and/or Ab3'; and induces the
production of a cellular response, as evidenced in part by the production of T-cells
that are specific for the binding agent, the binding agent/antigen complex, and/or
the antigen.

6 The present invention also includes methods and compositions for altering
the immunogenic state of the host organism. In altering the immunogenic state, the
compositions and methods of the present invention decrease, increase, or maintain
the host's immunogenic state. In a most preferred embodiment of the invention,
the methods and compositions do not decrease the antigenicity of the active
component in the therapeutic composition. The present invention is preferably a
11 method for increasing the over-all host response to a disease or condition.

The present invention also is a therapeutic composition comprising an active
agent, or binding agent, that specifically binds to a pre-determined soluble antigen,
wherein the binding agent, upon binding to the soluble antigen, forms a complex
that is both antigenic and immunogenic.

16 The compositions and methods of the present invention may also include
one or more steps or substances that increase the over-all immunogenicity.

The therapeutic compositions and methods of the present invention are
suitable for the treatment of any disease or cancer that produces a soluble antigen,
preferably a multi-epitopic antigen.

21 The present invention also includes a method for designing new therapeutic
agents comprising selecting a soluble antigen, preferably an antigen that has been
determined to be multi-epitopic; and selecting a binding agent that specifically binds
to said antigen to form a complex. In accordance with the invention, the binding
agent, the binding agent/antigen complex, and/or the antigen lead to the
26 production of a humoral and/or cellular response *in vivo*. In a preferred
embodiment of the invention, the method for designing a new therapeutic agent
results in a binding agent or the binding agent/antigen complex that induces the

1 production of a humoral response, as evidenced in part by the production of anti-tumor or anti-inflammation antibodies, Ab3 and/or Ab3'; and induces the production of a cellular response, as evidenced in part by the production of T-cells that are specific for the binding agent, the binding agent/antigen complex, and/or the antigen.

6 Although several investigators have shown that antigen-specific antibodies can enhance the immune response to those antigens presented in a complex form, the present invention is the first to demonstrate that the injection of an antibody against a single epitope can induce a multi-epitopic immune response in cancer patients, provided that the patients' sera contained the respective antigen. The present invention also demonstrates that this antibody injection can change the patient's immune response in such a way that the self-protein CA125 can now be recognized by the immune system.

11 Stimulation of T cells reactive with subdominant or cryptic epitopes of self-proteins has been suggested as an important factor in inducing immunity to a pre-determined antigen, e.g., an antigen involved in a disease or condition such as cancer or auto-immunity. Antibody-enhanced or -altered presentation of an antigen, such as CA125, in an antibody complex, e.g., bound to MAb-B43.13, by B cells (antibody-specific) or macrophages (F_c receptor mediated) may result in presentation of different peptides to the immune system than those obtained by presentation of the antigen alone. This can lead to sufficient presence of antigen-specific peptides from subdominant or cryptic epitopes which may in turn stimulate low-affinity T cells that escaped clonal deletion in the thymus or re-stimulate T cells which were suppressed. The immune response induced by exogenous administration of an antibody to a circulating self-antigen can therefore be compared to that observed in auto-immune diseases. This may also explain why presence of immune complexes of antigen with autologous human antibodies is often not correlated with improved survival. Human B cells recognize preferably

1 immune-dominant epitopes of the antigen, leading to presentation of epitopes
against which T cells were formed during fetal development. Murine antibodies on
the other hand, recognize immune-dominant epitopes in mice which are not
necessarily equivalent to the human immune-dominant epitopes.

6 The capture and processing of an antigen, e.g., PSA, by B-cells may also
occur through the interaction of the membrane bound Ab2 with the anti-
antigen/antigen (e.g., anti-PSA/PSA) complexes and in a similar manner through
the interaction of membrane bound Ab3 with the antigen (complexed or not with
the anti-PSA antibody).

11 Although applicants do not wish to be bound by any particular theory of
operability, it is believed that the observed immunological response achieved by the
present invention is attributable to an interaction between a newly formed antigen
and the human patient's immune system. A portion of the immune response
includes inducing the production of anti-(anti-idiotypic) antibodies by the patient.
16 Within this set of anti-(anti-idiotypic) antibodies are those that are directly
complimentary to the paratope of an anti-idiotypic antibody. It is further believed
that the paratope of the anti-idiotypic antibody presents an "internal" image of the
tumor cell epitope identified (i.e., selectively bound) by the idiotypic antibody and ,
therefore, the anti-(anti-idiotypic) antibodies will also bind the tumor antigen. In
effect, the present method induces a immunological response to the first antigen,
21 e.g., a tumor antigen, by presenting a second antigen (the paratope of the anti-
idiotypic antibody, which is essentially indistinguishable from the tumor antigen) to
a portion of the patient's resulting antibodies.

26 Many human diseases are characterized by excessive or inappropriate
immune responses. As used herein, these are undesirable or non-therapeutic effects.
For example, in transplantation, the immune system attacks MHC-disparate donor
tissue leading to graft rejection, in autoimmune disease it attacks normal tissues, and
in allergy the immune system is hyper-responsive to otherwise harmless

1 environmental antigens. It is now recognized that immunosuppressive therapy
may be appropriate for treating each of these disorders.

The present invention concerns altering immunogenicity in a manner that
produces a beneficial or therapeutically desirable effect. As used herein, a beneficial
or desirable immune response is one that produces a therapeutically desirable result.
6 For example, for a cancer such as ovarian cancer, a beneficial or desirable immune
response includes the production of an antibody that immunoreacts with a
previously non-immunoreactive ovarian cancer antigen. In this example, the
immune response to an antigen is increased. In another example, for a condition
such as inflammation, a beneficial or desirable immune response includes the
11 production of an antibody that immunoreacts with a previously immunoreactive
antigen so that it becomes non-immunoreactive. In this example, the immune
response is decreased.

Description of the Figures

Figure 1 is a graphic representation of the different types of antibodies and
16 their structural relationship to each other and to an antigen.

Figure 2 shows that a composition of the invention induces an immune
response against a tumor associated antigen.

Figure 3 shows tumor cell lysis caused by administering a composition of the
present invention.

21 Figure 4 shows the production of Ab2 in response to the administration of a
composition of the invention.

Figure 5 shows the production of B cells in response to the administration of
a composition of the invention. Legend: open bars, 0.1 μ g or kU per mL; hatched
bars, 1 μ g or kU per mL; closed bars, 10 μ g or kU per mL.

26 Figure 6 shows that a binding agent/antigen complex stimulates an immune
response. Legend: open bars, 0.1 μ g or kU per mL; hatched bars, 1 μ g or kU per

1 mL; closed bars, 10 μ g or kU per mL.

Figure 7 shows the ability of a composition of the invention to increase the immunogenicity of its target antigen. Legend: •, MAb 43.13; ■, MAb 43.13 + CA 125; ▲, CA 125.

6 Figure 8 shows the effect of a composition of the invention on the survival of tumor-bearing human-PBL-SCID/BG mice. Legend: ♦, MAb-B43.13 + PBL; ■, MAb-170 + PBL; ▲, PBS + PBL; •, tumor only.

Figure 9 shows the effect of a composition of the invention on tumor size of tumor-bearing human-PBL-SCID/BG mice. Legend: ♦, MAb-B43.13 + PBL; ■, MOPC21 + PBL; ▲, MAb 43.13; •, MOPC21.

11 Figure 10 shows the effect of a composition of the invention on tumor prevention for tumor-bearing human-PBL-SCID/BG mice. Legend: ♦, MAb-B43.13 + PBL; ■, MOPC21 + PBL; •, tumor only.

16 Figure 11 shows the effect of a composition of the invention on tumor size for tumor-bearing human-PBL-SCID/BG mice. Legend: ♦, MAb-B43.13 + PBL; ■, MOPC21 + PBL; •, tumor only.

Figure 12 shows a humoral response generated by a composition of the invention directed against breast cancer.

Figure 13 shows a humoral response generated by a composition of the invention directed against breast cancer.

21 Figure 14 shows a cellular response generated by a composition of the invention directed against breast cancer.

Figure 15 shows a reduction in breast tumor growth rate after administration of a composition according to the invention.

26 Figure 16 shows that AR 44.6 and AR 44.4 binding agents are effective in complement-mediated cytotoxicity.

Figure 17 shows the reduction in gastro-intestinal tumor volume after administration of a composition of the invention.

1 Figure 18 shows the amino acid sequence of a prostate-specific antigen binding site.

 Figure 19 shows the results and characteristics of an anti-inflammatory composition according to the invention.

6 Figure 20 shows the survival curves after administering HBBA-R2-SIL, in combination with photodynamic therapy.

Disclosure of the Invention

11 The present invention comprises a method for increasing the immunogenicity of an administered composition by target selection, by activation methodologies, and by delivery systems that, in combination, induces either cellular or humoral immunity, or both. The present invention involves the discovery that binding a binding agent to a soluble antigen, such as a multi-epitopic tumor-associated antigen, increases the immunogenicity of the immunogen while maintaining its antigenicity, and leads to the generation of a humoral and/or cellular response to the immunogen. The methods and compositions of the present invention typically allow or promote a host's ability to generate an immune response to a previously non-immunogenic antigen. In this manner, the host immune system can recognize and initiate an immune response to the previously unrecognized antigen.

16 An additional composition of the present invention may also include a modified antigen, wherein a soluble, preferably multi-epitopic, antigen is modified by binding to a binding agent. An additional method of the present invention may include producing the modified antigen, and/or using the modified antigen to achieve a therapeutic effect, e.g., producing or inducing an immune response against the antigen.

21 In accordance with the present invention, the inventors believe the

1 interaction between the antigen and the binding agent effectively presents a
previously unexposed or suppressed epitope to the patient's immune system to
generate: 1) a humoral response resulting in human anti-tumor antibodies that may
or may not be inhibitable by the injected antibody, but are definitely inhibitable by
an antibody that binds to an epitope different from the epitope reactive with the
6 injected BA; and 2) a cell-mediated response resulting in the production of antigen-
specific T-cells.

As noted above, the inventors believe that an important aspect of generating
a cellular and humoral response lies in part in increasing the immunogenicity of the
binding agent-antigen complex while maintaining its antigenicity. As described in
11 more detail below and in the Examples, increasing immunogenicity while
maintaining antigenicity may be affected by one or more of the following:

1. Administering a dose of binding agent that is low in
comparison to the dose for other therapeutic compositions;
2. Forming a binding agent-antigen complex *in vivo* or *ex*
16 *vivo*;
3. Photoactivating the binding agent prior to administration
4. Administering the binding agent in a microsphere,
liposome, nanosphere, or micelle;
5. Conjugating the binding agent to a photodynamic agent,
such as hypocrellin B; and
- 21 6. Conjugating the binding agent to immune effectors.

In a preferred embodiment of the invention, a composition comprising a pre-
determined antibody that specifically binds to a pre-determined tumor associated
antigen is used to bind a soluble antigen produced by the tumor. Once the soluble
antigen is bound, the immune system recognizes the antigen as "foreign," and
26 mounts an immune response against the antigen or against the binding agent bound

1 to the antigen. Antigens that can be made immunogenic are potentially useful to induce or activate an immune response, leading to therapeutic and possibly prophylactic benefits.

Any composition that includes a binding agent according to the invention may be used to initiate an *in vivo* immune response. The composition may include one or more adjuvants, one or more carriers, one or more excipients, one or more stabilizers, one or more imaging reagents, one or more effectors; one or more photodynamic agents; and/or physiologically acceptable saline. Generally, adjuvants are substances mixed with an immunogen in order to elicit a more marked immune response. Control vaccinations without the adjuvant resulted in humoral immune responses.

In a preferred embodiment of the invention, a suitable composition includes a binding agent that binds to a soluble antigen to form a complex that is itself antigenic and immunogenic. In a most preferred embodiment of the invention, the complex is an antigen that induces a beneficial or desirable therapeutic effect.

The composition may also include pharmaceutically acceptable carriers. Pharmaceutically accepted carriers include but are not limited to saline, sterile water, phosphate buffered saline, and the like. Other buffering agents, dispersing agents, and inert non-toxic substances suitable for delivery to a patient may be included in the compositions of the present invention. The compositions may be solutions suitable for administration, and are typically sterile and free of undesirable particulate matter. The compositions may be sterilized by conventional sterilization techniques.

In accordance with the teachings of the present invention, the methods and compositions produce both a humoral and cellular response. Those skilled in the art will readily recognize that determining that a humoral and/or cellular response has been generated is easily shown by testing for the structures associated with each response. For example, evidence of the production of a humoral response includes

1 but is not limited to the production of Ab2 and Ab3. Likewise, evidence of the
production of a cellular response includes but is not limited to the production of T2
and/or T3 cells.

BINDING AGENTS

6 The binding agents of the present invention bind the soluble antigen of
interest, and the resulting immunogenic pair may be used to prime or initiate an
immune response to another epitope on the complex or a portion of the complex.
The previously unrecognizable epitope, upon being recognized by agents of the
immune system, initiates the immune system cascade that results in an immune
response to the whole antigen.

11 A binding agent (BA), as used herein, refers to one member of an
immunologic pair, e.g., a binding moiety that is capable of binding to a single
epitope expressed on the tumor antigen. Exemplary binding agents include, but are
not limited to: monoclonal antibodies ("MAb"); chimeric monoclonal antibodies
("C-MAb"); humanized antibodies; genetically engineered monoclonal antibodies
("G-MAb"); fragments of monoclonal antibodies (including but not limited to
16 "F(Ab)₂", "F(Ab)" and "Dab"); single chains representing the reactive portion of
monoclonal antibodies ("SC-MAb"); tumor-binding peptides; a protein, including
receptor proteins; peptide; polypeptide; glycoprotein; lipoprotein, or the like, e.g.,
growth factors; lymphokines and cytokines; enzymes, immune modulators;
21 hormones, for example, somatostatin; any of the above joined to a molecule that
mediates an effector function; and mimics or fragments of any of the above. The
antibody may be a polyclonal antibody or a monoclonal antibody. The binding
agent may be labeled or unlabeled, but is preferably unlabeled. Antibodies and
antibody fragments are preferred. In a most preferred embodiment of the
26 invention, the binding agent is an Ab1 antibody that induces the production of one
or molecules that comprise an immune response, including but not limited to one

1 or more of the following: molecules associated with a cellular response, molecules
associated with a humoral response, Ab3, Ab3', ADCC, CDC, cytokines,
chemokines, cytotoxic T lymphocytes (CTL), and natural killer cells (NK).

6 The antibody may be obtained by immunizing any animal capable of
mounting a usable immune response to the antigen, such as a mouse, rat, goat sheep,
rabbit or other suitable experimental animal. In the case of a monoclonal antibody,
antibody producing cells of the immunized animal may be fused with "immortal"
or "immortalized" human or animal cells to obtain a hybridoma which produces
the antibody. If desired, the genes encoding one or more of the immunoglobulin
chains may be cloned so that the antibody may be produced in different host cells,
11 and if desired, the genes may be mutated so as to alter the sequence and hence the
immunological characteristics of the antibody produced. Fragments of binding
agents, may be obtained by conventional techniques, such as by proteolytic
digestion of the binding agent using pepsin, papain, or the like; or by recombinant
DNA techniques in which DNA encoding the desired fragment is cloned and
16 expressed in a variety of hosts. Irradiating any of the foregoing entities, e.g., by
ultraviolet light will enhance the immune response to a multi-epitopic antigen under
similar conditions. In a preferred embodiment of the invention, effector functions
that mediate CDC or ADCC are not required.

21 One of the most promising approaches to tumor immunotherapy is to use
antibody fragments or antibody fragments with effector domains to target and kill
tumor cells. Single-chain Fv (scFv) has been genetically engineered as a recombinant
fusion protein that is composed of a heavy chain (Vh) and a light-chain (Vl) variable
domain connected by an artificial linker.

26 The prospect of scFv mediated bi-functional molecule is encouraging for
number of reasons. If it is possible to produce them in bacteria and/or yeast
expression systems then this might lead to lower costs. In general, smaller
immunoglobulin forms such as scFv appear to be of greater advantage. This small

1 molecule has shown increased accessibility to tumor cells *in vivo* and may therefore be better than MAb for use in drug, radionuclide or hormone delivery systems.

6 The Fv fragments of immunoglobulins have many significant advantages over whole immunoglobulins for the purpose of medical imaging and for targeted tumor therapy, including better lesion penetration on solid tumor tissue and more rapid blood clearance, as well as potentially lower Fc-mediated immunogenicity. The single-chain Fv (scFv) in this study was engineered from the genes isolated from the variable regions of anti-CA125 (tumor marker expressed in 80% of all ovarian carcinomas) antibody.

11 In an embodiment of the invention, a suitable composition for the treatment of an ovarian tumor associated antigen contains a binding agent that binds the CA 125 antigen. In another embodiment of the invention, a suitable composition for the treatment of gastrointestinal cancer contains a binding agent that binds the CA 19.9 antigen. In yet another embodiment of the invention, a suitable composition for the treatment of breast cancer contains a binding agent that binds the CA 15.3 antigen. Various binding agents, antibodies, antigens, and methods for preparing, isolating, and using the antibodies are described in U.S. Patent 4,471,057 (Koprowski) and U.S. Patent 5,075,218 (Jette, et al.), both incorporated herein by reference. Furthermore, many of these antibodies are commercially available from Centocor, Abbott Laboratories, Commissariat a L'Energie Atomique, Hoffman-LaRoche, Inc., Sorin Biomedica, and FujiRebio.

21 As noted in the background section, the potential effect of injecting a binding agent such as an antibody can be extremely complex and may typically involves distinct mechanisms of action. As used in herein, Ab3 and Ab3' represent two such distinct mechanisms that individually and/or collectively produce a beneficial effect. In the Ab3 pathway, an Ab1 antibody that is capable of binding to a pre-determined antigen may induce the production of an anti-idiotypic antibody (Ab2 β) that mimics an epitope of the antigen. The anti-idiotypic antibody in turn

1 may induce the production of anti-anti-idiotypic antibodies (Ab3) that are capable of
binding the same epitope on the antigen as the Ab1 antibody. Evidence of this
pathway includes a competitive assay between Ab1 and Ab3, since the Ab1
antibody and the Ab3 antibody compete for the same epitope of the antigen.

6 In the Ab3' pathway, the Ab1 antibody binds to the antigen to form a
complex. This complex is itself an antigen, and is sometimes described herein as a
"modified antigen" or second antigen. The complex may induce the production of
anti-antigen antibody (Ab3') that are capable of binding a different epitope on the
antigen as that bound by the Ab1 antibody. Evidence of this pathway also includes
a competitive assay, but comparing the inhibitory effect on Ab3' by antibodies that
11 bind to different epitopes on the antigen or lack of inhibition with Ab1.

In addition to producing Ab3 and/or Ab3', typically associated with a
humoral immune response, the compositions of the present invention may also
produce a therapeutic benefit by inducing a cellular immune response (cell mediated
immunity), as in the Background section. Both the cellular and the humoral
16 response involve indirect mechanisms for altering the immunogenicity of the host.

Compositions of the present invention may also initiate direct mechanisms
for killing undesirable cells such as cancer cells. For example, in antibody-
dependent cell-mediated cytotoxicity (ADCC), an Ab1 antibody, bound through its
Fab region to a pre-determined antigen, may bind to the Fc receptor of a
lymphocyte through the Fc region of the Ab1 antibody. Such participation
21 between an antibody and immune system cells produces an effector function that
may lyse tumor cells, infectious agents, and allogeneic cells. Other indirect
mechanisms involve complement-mediated cytotoxicity (CDC), apoptosis,
neutralization of immunosuppressive tumor-associated antigens, induction of
26 cytokines and/or chemokines, neutralization of immunosuppressive molecules, and
neutralization of anti-adhesion molecules, among others.

As used herein, a comprehensive approach to providing a therapeutic benefit

1 involves one or more, or all, of the following: cellular immunity and the molecules
involved in its production; humoral immunity and the molecules involved in its
production; ADCC immunity and the molecules involved in its production; CDC
immunity and the molecules involved in its production; natural killer cells;
cytotoxic T lymphocytes, and the molecules and cells involved in their production;
6 and cytokines and chemokines, and the molecules and cells involved in their
production.

SOLUBLE ANTIGEN

The binding agent may be directed against any antigen of clinical
significance, but preferably is directed against a tumor-associated antigen (TAA). In
11 the case of TAA, the cancer may include, but is not limited to lung, colon, rectum,
breast, ovary, prostate gland, head, neck, bone, immune system, or any other
anatomical location. The subject may be a human or animal subject. Illustrative
tumors and tumor markers are listed in U.S. Patent 5,075,218.

16 The methods of the present invention involve any cancer that produces a
soluble multi-epitopic TAA. As used herein soluble is used to describe any antigen
that is detectable in a body fluid, i.e., blood, serum, ascites, saliva, or the like. In
accordance with the present invention, the preferred tumors are those that: shed
soluble tumor antigens, e.g., tumor antigens shed into the bloodstream, as opposed
to a surface antigen or an intracellular antigen; exhibit a multi-epitopic tumor
associated antigen, preferably of carbohydrate or glycoprotein (e.g., mucin) nature;
21 and can be found at a concentration in the patient's body fluid more than is
normally present in healthy controls and such a high level signifies a poor prognosis
for the patient, yet has not initiated an immune response. As is well known by one
skilled in the art, one method of determining whether the concentration of the
26 TAA is greater than is predictive of recurrence of the disease is by comparing the
patient's concentration to that of a healthy control. If the concentration of the

1 TAA is higher than the healthy control, then the patient's concentration is
predictive of poor prognosis of the disease.

The invention also involves the production of a modified antigen, typically
by producing the modified antigen *in vivo*. As used herein, modified antigen refers
to a first antigen, typically invisible to the immune system, that binds to a binding
6 agent, and the binding agent-antigen is itself an antigen (the "second" antigen) that is
immunoreactive with one or more molecules of the immune system.

As used herein, "disease" refers to the management, diagnosis, and/or
palliation of any mammalian (including human) disease, disorder, malady, or
condition. "Disease" includes but is not limited to cancer and its metastases, such as
11 skin cancer; growths or tumors, and their metastases; tumors and tumor cells, such
as sarcomas and carcinomas, including solid tumors, blood-borne tumors, and
tumors found in nasal passages, the bladder, the esophagus, or lung, including the
bronchi ; viruses, including retroviruses and HIV; bacterial diseases; fungal diseases;
and dermatological conditions or disorders, such as lesions of the vulva, keloid,
16 vitiligo, psoriasis, benign tumors, endometriosis, Barrett's esophagus, *Tinea capitis*,
and lichen amyloidosis. Exemplary soluble multi-epitopic antigens are described
above, and include but are not limited to CA 125, CA 19.9, CA 15.3, and prostate
specific antigen.

IMMUNOGENICITY ENHANCERS

1. LOW DOSE

In accordance with the methods of the present invention, a composition
comprising the binding agent may be administered in an amount sufficient to
recognize and bind the pre-determined antigen, such as a tumor associated antigen
(TAA), preferably a soluble multi-epitopic antigen. In a preferred embodiment of
26 the invention, the dosage is sufficient to generate or elicit an immune response
against the antigen. See Example 20. An immunologically or therapeutically

1 effective or acceptable amount of binding agent is an amount sufficient to bind a
pre-determined antigen *in vivo* or *ex vivo*, and is capable of eliciting an immune
response to the antigen. The response inhibits or kills tumor cells that carry and
present a newly accessible epitope, thereby ameliorating or eliminating the disease
or condition that produces the antigen. The immune response may take the form of
6 a humoral response, a cell-mediated response, or both. In a preferred embodiment
of the invention, the dosage of the monoclonal antibody is less than the dosage
required to elicit ADCC or CDC.

The concentration or dosage of the protein in the composition can vary
widely, e.g., from less than about .01% to about 15 to 20% by weight. As noted
11 above, the composition is administered in an amount sufficient to stimulate an
immune response against the antigen. Amounts effective for this use will depend in
part on the severity of the disease and the status of the patient's immune system.
Generally, the composition will include about 0.1 μ g to about 2 mg or more of
16 protein agent per kilogram of body weight, more commonly dosages of about 1 μ g
to about 200 μ g per kilogram of body weight, recognized by those skilled in the art
as comprising a low dose. Further, those skilled in the art will recognize and be
able to evaluate the various considerations that may be used to determine a proper
dose. The concentration will usually be at least 0.5%; any amount may be selected
primarily based on fluid volume, viscosity, antigenicity, etc., in accordance with the
21 particular mode of administration.

2. PHOTOACTIVATION

In accordance with the present invention, an antibody may be
photoactivated. Processes for photoactivating a binding agent are extremely well
known in the art, and include exposing the antibody to radiation, wherein the
26 resulting altered antibody is capable of generating an immune response when
administered to an animal typically capable of generating an immune response to

1 the native form of the antibody.

In a preferred embodiment of the invention, the antibody is exposed to ultraviolet light. Typically, the antibody may be exposed to ultraviolet light at a wavelength from about 200 nm to about 400 nm, at from about .1 to about 1000 Joules/cm², for from about 1 to about 180 minutes (more preferably, about 10 to about 30 minutes).

3. DELIVERY SYSTEM

Since some binding agents such as proteins are by themselves poor immunogens, their immunogenicity may be augmented by administration in immunological adjuvants and antigen delivery systems. The immunogenicity of a specific composition may also be increased or optimized by choice of delivery route. For example, the immunogenicity of compositions produced in accordance with the present invention that include a monoclonal antibody may be increased by choosing a mode of delivery that increases the direct contact between the binding agent and the antigen. The preferred route is intravenous. Those skilled in the art are conversant with the various choices available, and why one route might be chosen over another route for a particular binding agent.

One skilled in the art will also recognize that liposomes, nanospheres, micelles, or microspheres may be used to administer a composition, and that such administration may increase immunogenicity.

4. PHOTSENSITIZER

Compositions of the present invention may include one or more photosensitizers. Exemplary photosensitizers include, but are not limited to fluorescein, hematoporphyrin derivatives (e.g., Photofrin®), porphyrin derivatives, and perylenequinoid pigments. In a preferred embodiment of the invention, the photosensitizer comprises the use of perylenequinone (PQP) derivatives as

1 photodynamic agents, and the use of PQP derivatives in immunophotodynamic
therapy (IPT).

6 The invention also comprises a method of treating a disease by administering
a therapeutically sufficient amount of at least one PQP derivative bound to a
binding agent, and activating the conjugate, typically by photoactivating the PQP
derivative. Typically, the PQP derivative may be activated by exposing the
derivative to a pre-determined wavelength of light. The invention also includes a
method of treating cancer which is enhanced in the presence of light wavelengths
between about 400 nm and about 850 nm. Suitable PQPs include, but are not
limited to those disclosed in U.S. Serial No. 08/782,048, incorporated herein by
reference. In a preferred embodiment of the invention, the PQP is hypocrellin B,
molecules derived from HB, and compositions that include HB or one or more of
its derivatives.

21 The desired characteristics for a PDT sensitizer comprise at least one or
more of the following characteristics: good absorption of light in a wavelength that
penetrates tissue to the desired depth (absorption in the 600 nm to 850 nm range
penetrate the skin many mm), compound sensitive to pH - inactive, lower activity
or activity destroyed at the pH characteristic of normal tissues, but active or higher
activity at the pH of the cells or organisms to be treated; compound cleared from
the body quickly and if a compound is intended to treat solid tumors it should have
the ability to function either in the presence and/or absence of oxygen to address
the problem of tumor cell hypoxia. The photosensitizer should have low dark
cytotoxicity, and excellent photopotential of cellular damage. The PDT toxic
effect may be mediated via necrotic, apoptotic cell death, or by stasis of the tumor
vasculature or vascular bed.

26 5. EFFECTORS

The present invention includes a composition comprising a binding agent

1 bound to or used in conjunction with one or more effectors. As used herein,
effector refers to a substance that affects the activity of the binding agent without
binding to the substrate (or antigen) binding site.

A conceptually straightforward method to functionalize recombinant
antibodies consists of sequentially fusing the antibody gene with the gene of a
6 second protein, and expressing the resulting fusion protein as a single protein.
Exemplary second proteins include but are not limited to:

a. A signal amplification moiety, such as a biotin mimetic sequence, which
can be introduced at the C-terminus of a binding agent as a detection tag because of
strong affinity of streptavidin-biotin;

11 b. liposomes: fuse certain amino acid sequences (with negative charges
under physiologic condition) with a binding agent, such as single chain Fv-B43.13.
Therefore, the fusion protein can easily be trapped by liposomes;

16 c. cytokine sequences (e.g. IL-2): IL2 is a lymphokine synthesized and
secreted primarily by T helper lymphocytes which have been activated by
stimulation of the T cell receptor complex with antigen/MHC complexes on the
surfaces of antigen-presenting cells. The response of T helper cells to activation is
induction of the expression of IL2 and of receptor of IL2. IL2 possesses a variety of
other activities which affect B cell growth and differentiation, formation of LAK
cells, and augmentation of NK cells and enhancement of their cytolytic activity.
21 Because of the central role of the IL2/IL2 receptor system in mediation of the
immune response, it is obvious that manipulation of this system has important
therapeutic implications. IL2 has already shown promise as an anti-cancer drug by
its ability to stimulate the proliferation and activities of tumor attacking LAK and
TIL cells.

26 d. toxin: immunotoxins made by attaching a toxin (e.g. Pseudomonas
extoxin and bacteria RNase) to the antibody or antibody fragments to produce
cytotoxic molecules that selectively kill target tumor cell.

1 e. enzyme: an antibody-directed enzyme pro-drug therapy system is a particularly attractive artificial effector method. In this approach, an antibody is used to target an enzyme to the tumor, and to retain it while the antibody-enzyme conjugate clears from normal tissues. A non-toxic pro-drug is then administered, and this is activated by the enzyme to produce a cytotoxic drug at the tumor site.

6 f. radionuclide chelator: any peptide that binds to a radionuclide chelator, e.g., metallothionein (MT). MT is a ubiquitous, low-molecular weight, metal-binding protein that participates in metal metabolism and detoxification. Mammalian forms of MT bind seven ions in tetrahedral metal-thiolate clusters, including technetium and other metals useful for targeted radiodiagnosis or therapy. 11 The highly conserved MT structure offers the additional advantage of low-to-nonexistent immunogenicity.

16 G. A phagocytosis enhancer, e.g., tuftsin. Tuftsin is natural tetrapeptide (Thr-Lys-Pro-Arg) that was found to manifest several biological activities, including activation of macrophages/monocytes and stimulation of phagocytosis. It has a wide spectrum of immunoadjuvant activities which it exerts on the phagocytic cells, the polymorphonuclear leukocyte, the monocyte and the macrophage. In animal and clinical studies, tuftsin has displayed anti-tumor, anti-infection activity with no detectable toxicity.

21 The fusion protein scFv-tuftsin was defined as a recombinant fusion protein that is composed scFv antibody binding domain connected with tuftsin by an artificial linker. This bi-functional protein was designed to achieve higher specific anti-idiotypic immunogenicity. The strategies used to produce scFv-tuftsin protein relied on the methylotrophic yeast *P. pastoris* expression/secretion system that has been developed to the overproduction of a variety of eukaryotic proteins with high secretion-efficiency. In this system, a foreign gene is inserted in the place of the *P. pastoris* alcohol oxidase (AOX1) gene and the expression of the cloned gene is thus 26 under the control of the strong and methanol inducible AOX1 gene promoter.

METHOD

As used herein, "administering" refers to any action that results in exposing or contacting a composition containing a binding agent with a pre-determined cell, cells, or tissue, typically mammalian. As used herein, administering may be conducted *in vivo*, *in vitro*, or *ex vivo*. For example, a composition may be administered by injection or through an endoscope. Administering also includes the direct application to cells of a composition according to the present invention. For example, during the course of surgery, tumor cells may be exposed. In accordance with an embodiment of the invention, these exposed cells (or tumors) may be exposed directly to a composition of the present invention, e.g., by washing or irrigating the surgical site and/or the cells.

For diseases that can be characterized in part by having a tumor-associated antigen that is multi-epitopic, the present invention involves contacting a soluble antigen with a binding reagent (BA) that specifically binds to a single epitope on the multi-epitopic tumor-associated antigen.

In accordance with a method of the invention, the binding agent must be capable of binding a pre-determined binding site or receptor, and may be administered to the patient by any immunologically suitable route. For example, the binding agent may be introduced into the patient by an intravenous, subcutaneous, intraperitoneal, intrathecal, intravesical, intradermal, intramuscular, or intralymphatic routes. The composition may be in solution, tablet, aerosol, or multi-phase formulation forms. Liposomes, long-circulating liposomes, immunoliposomes, biodegradable microspheres, micelles, or the like may also be used as a carrier, vehicle, or delivery system. Furthermore, using *ex vivo* procedures well known in the art, blood or serum from the patient may be removed from the patient; optionally, it may be desirable to purify the antigen in the patient's blood; the blood or serum may then be mixed with a composition that includes a binding agent according to the invention; and the treated blood or serum

1 is returned to the patient. The clinician may compare the anti-idiotypic and
anti-isotypic responses associated with these different routes in determining the
most effective route of administration. The invention should not be limited to any
particular method of introducing the binding agent into the patient.

Administration may be once, more than once, and over a prolonged period.
6 As the compositions of this invention may be used for patient's in a serious disease
state, i.e., life-threatening or potentially life-threatening, excesses of the binding
agent may be administered if desirable. Actual methods and protocols for
administering pharmaceutical compositions, including dilution techniques for
injections of the present compositions, are well known or will be apparent to one
11 skilled in the art. Some of these methods and protocols are described in
Remington's Pharmaceutical Science, Mack Publishing Co. (1982).

A binding agent may be administered in combination with other binding
agents, or may be administered in combination with other treatment protocols or
agents, e.g., chemotherapeutic agents.

16 The effectiveness of the proteins of the present invention may be monitored
in vitro or *in vivo*. Humoral responses may be monitored in vitro by conventional
immunoassays, where the anti-tumor activity of the response may be determined by
complement-mediated cellular cytotoxicity and/or antibody-dependent cellular
cytotoxicity (ADCC) assays. The assay methodologies are well know, and are
described in *Handbook of Experimental Immunology*, Vol. 2, Blackwell Scientific
Publications, Oxford (1986). Other assays may be directed to determining the level
of the antigen in the patient or tissue. Cell-mediated immunity may be monitored
21 *in vivo* by the development of delayed-type hypersensitivity reactions, or other *in*
vivo or *in vitro* means known to those skilled in the art, including but not limited
to the skin test reaction protocol, lymphocyte stimulation assays, measuring the
toxicity of a subject's lymphocytes to tumor cells by using a standard cytotoxicity
26 assay, by a limiting dilution assay, or by measuring plasma levels of cytokines using

1 standard ELISA assays.

Determining the effectiveness of a specific binding agent – antigen pair may also be accomplished by monitoring cell killing. Those skilled in the art will recognize that there are a variety of mechanisms that are proof of cell killing. As shown in the Examples, cell killing may be demonstrated by showing that Ab3 mediates ADCC, that Ab1 and HAMA mediates CDC, that natural killer (NK) cells are produced, and/or that cytotoxic T lymphocytes (CTLs) are produced.

EXAMPLES

Example 1. Antibody mediated immunotherapy influence of circulating antigen in inducing antigen specific anti-tumor immune responses.

This example demonstrates the use of antigen-specific murine monoclonal antibodies to induce an immune response against an immune-suppressive tumor-associated antigen. Injecting an antibody against a specific epitope in a multi-epitopic antigen can lead to immune responses against various other epitopes on this antigen.

In an attempt to understand the mechanism of action of MAb-B43.13, various immunological parameters were studied in patients injected with this antibody. These studies clearly demonstrated activation of both the humoral and cellular anti-cancer immune responses.

The generation of human CA125-binding antibodies was measured before and after MAb-B43.13 injection and correlated to pre-injection CA125 levels as well as to survival data. Tables 1 and Figure 2 show that generation of anti-CA125 antibodies correlates with CA125 pre-injection levels. Circulating CA125 affects the development of anti-CA125 antibodies only when patients received the MAb-B43.13 injection. If anti-CA125 antibodies before injection of MAb-B43.13 are compared between patients with low or high CA125 values (below or above 100 U/mL), no difference was found between the two groups (Table 1). A minimum concentration of 100 U/mL of CA125 was found to be necessary to see a statistically significant

1 difference in the anti-CA125 response.

Further, an increase in anti-CA125 antibodies was correlated with improved survival prognosis (Table 2). The difference in survival between anti-CA125 responders and non-responders was found to be statistically significant. The observation that MAb-B43.13 treated patients with high CA125 values had a better survival prognosis than those with low CA125 titers is very interesting, especially in view of reports indicating that high levels of mucin-like antigen is correlated with poor prognosis. Among patients with no humoral response to CA125, high circulating antigen levels were correlated with lower survival rates, as expected from the literature. In the other hand, high circulating CA125 levels were not considered a bad prognostic factor in patients, who developed anti-CA125 antibodies after MAB43-13 injection (Table 2). Anti-CA125 antibodies purified from these patients not only bound to human ovarian cancer cells but also mediated tumor killing via antibody-dependent cell-mediated cytotoxicity (ADCC). See Figure 3. It should be emphasized in this context that only one patient out of 52 showed detectable anti-CA125 antibodies before injection.

Table 1

Anti-CA125 Titer [ng/mL] Mean ± SD		Anti-CA125 Titer [ng/mL] Median	No. of Positives/ Total	% Positives	Significance P
No MAbB43.13 Injection					
CA125 < 100 U/mL	54.8± 27.5	45	0/14	0	0.264
CA125 > 100 U/mL	94.8± 212.7	50	1/38	2.63	
After MAb-B43.13 Injection					
CA125 < 100U/mL	100.0 ± 56.7	72.5	1/21	4.76	0.0072
CA125 > 100 U/mL	242.3± 327.1	137.5	15/50	30.0	

1

Table 2

	Survival [months]		Significance
	Mean \pm SD	Median	P
Anti-CA125 non-responders	37 \pm 18	38	
CA125 < 100 U/mL	44 \pm 26	40.5	
			0.3283
CA125 > 100 U/mL	30 \pm 14	30	
Anti-CA125 responders	70 \pm 43	49	
CA125 < 100 U/mL	57 \pm 22	45.5	
			0.0088
CA125 > 100 U/mL	83 \pm 48	58	
CA125 < 100 U/mL			
Anti-CA125 non-responders	44 \pm 26	40.5	
			0.2014
Anti-CA125 responders	57 \pm 22	45.5	
CA125 > 100 U/mL			
Anti-CA125 non-responders	30 \pm 14	30	
			0.0009
Anti-CA125 responders	83 \pm 48	58	

1 In an attempt to understand the mechanism behind anti-CA125 antibody
formation by MAb-B43.13 injection in cancer patients, we characterized the human
anti-CA125 antibodies present in their sera. For example, if the anti-CA125
antibodies were generated in the manner suggested by the idiotypic network, MAb-
B43.13 would generate anti-MAb-B43.13 antibodies, some of which would exactly
6 mimic the CA125 antigen (=Ab2 β). These in turn can generate anti-CA125
antibodies (=Ab3). The Ab3 generated through this pathway would bind to the
same epitope on CA125 as the Ab1 (=B43.13) and therefore compete with the
binding of MAb-B43.13 to the antigen.

11 On the other hand, antibodies generated through the antigen itself will bind
to various epitopes available on the antigen. If the anti-CA125 antibodies were
generated in a manner suggested by the present invention, the pathway would
follow Ab1 + soluble antigen \rightarrow Ab3'. Following this scheme, MAb-B43.13 (Ab1)
would bind the CA125 serum antigen, which would in turn generate an anti-CA125
antibody (Ab3'). Furthermore, the Ab3' antibodies generated under this pathway
16 would bind and be inhibited by other anti-Ca 125 antibodies, such as B27.1, because,
as noted above, CA125 is multi-epitopic and B43.13 and B27.1 epitopes are distinct;
also, Ab3' will not bind to anti-MAb-B43.13 antibodies.

21 Analysis of the serum samples with positive anti-CA125 titers demonstrated
that their binding to CA125 could be inhibited not only by MAb-B43.13 single
chain antibody but also by F(ab') fragments of other anti-CA125 antibodies, B27.1
and M11, that recognize epitopes on CA125 which are different from B43.13 (Table
3). Sera from only two patients were considered to contain anti-CA125 antibodies
that were exclusively generated via idiotype induction of MAb-B43.13 (=Ab3) i.e.
anti-CA125 antibodies that could only and completely be inhibited with MAb-
26 B43.13 and bound to polyclonal rabbit Ab2.

The presence of a multi-epitopic anti-CA125 response in sera of MAb-B43.13
treated patients with high CA125 levels make us believe that, besides anti-idiotype

1 induction, other mechanisms exist to induce an immune response against tumor-
associated antigens. In this scenario, the injected antibody forms a complex with the
circulating antigen in circulation. This process can cause several effects. The
complexation of the antigen by antibodies can facilitate the uptake of CA125 by
professional antigen-presenting cells (APC) and thus render the antigen more
6 immunogenic. The complexing antibody-- in our case from a murine source-- could
also function as an adjuvant, adding a foreign component to the self-antigen CA125
that might facilitate recognition by the immune system. Epitopes of the antigen are
blocked by the complexing antibody and are either protected from processing or
processed at different sequences thus creating new peptides for MHC-binding. It is
11 also possible that a conformational change in the antigen takes place upon antibody
binding thereby exposing new epitopes to the immune system, including sub-
dominant or immune-dormant epitopes.

It is interesting to note that the complex formation between CA125 and
MAb-B43.13 has also been observed during pharmacokinetic studies, as determined
by drop in circulating CA125 levels upon injection of MAb-B43-13. When patients
received more than one injection and patients developed high amounts of human
anti-mouse antibodies (HAMA), the antibody showed rapid clearance to liver and
spleen, as demonstrated in immunoscintigraphic studies. Antigen-antibody
complexes, accumulated in lymphoid centers like the spleen, are known to be very
efficiently presented to T cells by antigen-presenting cells like B cells or
21 macrophages.

Augmentation of antigen processing and presentation by immune
complexing has been demonstrated in several systems. Targeting tetanus toxoid to
FcγR by complexing with anti-tetanus toxoid IgG results in a 10-1000-fold increase
26 in processing and presentation of this antigen as measured by T_H cell activation. A
similar increase in immunogenicity was observed with hepatitis B antigen
complexed with its corresponding antibody. Also the natural presence of antibodies

against α -galactosyl epitopes has been used to augment tumor vaccine immunogenicity in α -galactosyl -modified tumor-associated antigens.

It was observed that MAb-B43.13 has a protective effect on its CA125 epitope during antigen processing by the immune system. The MAb-B43.13 epitope was recognized by almost all anti-CA125 antibody samples from patients (inhibition in 82% of the samples, Table 3).

The reverse seems to be true as well, i.e. CA125 has conserving properties on the idiotope of MAb-B43.13 during the antigen processing event. The increased formation of Ab2 in mice immunized with the CA125-MAb-B43.13 complex compared to mice immunized with MAb-B43.13-KLH (Figure 4) and the increased Ab2 production in MAb-B43.13 injected patients with CA125 titers above 100 U/mL confirm this observation. See Table 3 for a summary and Table 4 for the details of these results. Sera from these patients were analyzed for the presence of human anti-CA125 antibodies by their ability to bind to CA125 [R. Madiyalakan et al, *Hybridoma*, 14:199-203 1995) and Schultes et al., *Cancer Immunology and Immunotherapy* 46:201-212 (1998)].

Table 3

Inhibition No. of Positives/Total (%)			
CA125 10000 U/ml	B43.13 scFv 1 μ g/ml	B27.1 F(ab') 1 μ g/ml	M11 F(ab') 1 μ g/mL
26/28	23/28	19/28	12/18
(92.8)	(82.1)	(67.9)	(66.7)

TABLE 4: Characterization of Anti-CA125 Antibodies in Patients Injected with MAb-B43.13

Patient	Inj.#	Days Elapsed After Injection	Anti-CA125 Ab levels	Binding to Anti-MAb-B43.13 (Ab2) [†]	Inhibition [%]*			Classification
					CA125 10000 U/mL	B43.13 s. chain** 10 µg/mL	B27.1 F(ab')** 1 µg/mL	
1	3	0	14.8	+	62.3	42.6	5.8	Ab3
2	1	185	9.5	-	21.6	-46.9	-86.9	Ab3'
3	3	86	25.4	+	80.2	84.4	-0.5	Ab3
	3	207	48.7	+	91.4	94.0	-9.1	Ab3
	4	144	79.7	+	77.1	93.0	3.5	Ab3
	4	270	30.9	+	79.2	83.0	-55.8	Ab3
	4	309	16.7	+	77.0	83.0	-55.8	Ab3
	5	134	64.1	+	89.1	83.3	-37.3	Ab3
4	2	15	23.6	-	62.3	-84.8	-101.9	Ab3'
	2	41	21.6	-	56.9	20.2	-7.0	Ab3'
	2	76	23.1	-	63.6	29.4	4.5	Ab3'
	3	28	11.1	-	24.2	4.7	11.1	Ab3'
5	1	16	15.5	+	74.8	78.3	39.9	Ab3'/Ab3
6	3	0	10.3	+	54.0	60.2	22.7	Ab3'/Ab3
7			14.9	-	29.7	-70.2	-358.9	Ab3'
8	1	7	59.1	-	77.1	87.1	34.9	Ab3'
	1	17	46.9	-	78.4	86.5	40.7	Ab3'
9	3	112	9.2	-	-66.4	16.0	20.2	Ab3'
	3	166	8.5	-	-18.4	42.5	56.5	Ab3'
10	3	0	41.5	-	30.8	39.2	20.0	Ab3'
11	5	134	8.8	-	19.0	24.4	3.5	Ab3'
	6	134	8.7	-	18.0	39.0	46.0	Ab3'
	9	26	13.4	-	54.5	19.3	11.1	Ab3'
	9	65	13.3	-	56.1	24.4	3.7	Ab3'
	10	40	9.4	-	61.4	37.0	33.4	Ab3'
12	2	14	10.6	-	24.5	-54.4	19.9	Ab3'
13	1	15	11.5	-	30.8	47.4	55.8	Ab3'
14	2	17	10.1	-	30.3	-51.2	1.2	Ab3'

* To be considered to be significant, inhibition has to be at least 10%

** Single chain MAb-B43.13 and F(ab') MAb-B27.1 were used in the inhibition studies to avoid non-specific inhibition due to the Fc portion of the antibody and cross-reactivity due to HAMA.

† Anti-MAb-B43.13 (Ab2) was purified from rabbits injected with MabB43.13.

1 Therefore, complex formation can lead to enhanced anti-CA125 as well as anti-idiotypic antibody formation. Manca et al., *J. Immunol.* 140:2893 (1988) and Ling et al., *Immunology* 62:7 (1987) have shown that antibodies can preserve the sequence of their epitope during antigen-processing and antibodies have been used to raise immune responses to less immunogenic epitopes of an antigen.

6 Enhanced antigen-presentation of antigen-antibody complexes was attributed to facilitated antigen uptake via the Fcγ-receptor (macrophages, dendritic cells) or membrane-bound Ig (B cells) on professional antigen-presenting cells (APC). The human FcγRI and RIII-receptor on macrophages and dendritic cells does not bind murine IgG₁, but the human FcγRII, which mediates phagocytosis and pinocytosis of small immune complexes, has strong affinity to this murine IgG isotype.

11 Accordingly, various professional APC can be involved in the preferential presentation of the CA125-MAb-B43.13 complex. We tested B cells with two different specificities as well as macrophages as APC: CA125-specific B cells (from mice immunized with CA125) and anti-MAb-B43.13-specific B cells (from mice immunized with MAb-B43.13). Normal B cells served as control. When the proliferation of CA125-specific T cells was monitored by [methyl-³H]-Thymidine uptake, optimal stimulation was observed in MAb-B43.13 specific B cells, primed with the CA125-MAb-B43.13 complex (Figure 5), followed by presentation of CA125 by CA125-specific B cells. Enhanced presentation of immune complexes by macrophages and dendritic cells is mediated by preferential uptake via the FcγR. Figure 6 confirms that CA125 is presented more efficiently by macrophages, if complexed with an antigen specific antibody.

21 Thus, if the patients serum contained anti-CA125 antibodies that were inhibitable by MAb-B43.13 only, it was classified as containing Ab3; those inhibitable by MAb-B27.1 were classified as Ab3'. In other words, injecting a binding agent such as an antibody against a single epitope on a multi-epitopic antigen leads to generation of a humoral and cellular response against a different

1 epitope on the antigen.

The ability of MAb-B43.13 to increase the immunogenicity of Ca125 was studied in a mouse model by immunizing a mouse with the Ca125-MAb43.13 complex, compared to CA125 or MAb-B43.13 alone as the immunogen. When the mouse sera was analyzed for anti-CA125 antibody levels, the mice injected with the antigen-antibody complex had the highest titers (see Figure 7). This supports the observation that interaction of the antigen with a specific antibody leads to a higher antigen specific humoral immune response compared to antibody or antigen alone.

These results clearly indicate that when an antibody against a single epitope (B43.13) was injected into a patient, an antibody response against the whole antigen is generated which recognizes different epitopes present in the antigen. The presence of Ab3 in some patients could be explained by the likely presence of excess B43.13 epitope in the CA125 due to insufficient binding of the antibody to that portion of the B 43 epitope or idiotypic induction through Pathway I. Nevertheless, the predominant mechanism of the response seems to be through Pathway II. In other words, injecting a binding agent such as a monoclonal antibody to a soluble multi-epitopic antigen into a patient having a functioning immune system generates an antibody to the antigen, where the generated antibody is inhibited by antibodies to different epitopes.

Example 2.

Similarly, injecting the binding agent to the cancer patients having circulating CA125 lead to antigen specific CTL's. Peripheral Blood Mononuclear Cells (PBMC) from eight patients injected with MAb-B43.13 were tested for cytotoxicity against CA125 positive or CA125 negative ovarian tumor cells in a chromium release assay. The results are shown in Table 5. The specificity of the lysis was confirmed by the ability of MAb-B43.13 to inhibit such lysis, as well as the inability to kill CA125 negative tumor cells. Of the 8 patients who received MAb-

B43.13, at least four patients (#5 to #8) were determined to have CA125 specific cytotoxic T lymphocytes (CTL's) in their blood. The generation of CA125 specific CTL's are likely to kill ovarian tumor cells in patients.

TABLE 5: Cytotoxicity In Patients Injected With A Vaccine Containing MAb-B43.13

PATIENT ID	SAMPLE		PERCENT LYSIS			PERCENT INHIBITION BY MAb-B43.13 (5 µg)	PERCENT DIFFERENCE BETWEEN CA 125 positive and CA 125 negative CELLS
	Injection Number	Days Post Injection	CAOV-4	SK-OV-3	K562		
1	2	17	2.0	0.0	3.7	ND*	insignificant
2	2	0	9.8	7.5	33.5	ND	31
3	3	0	22.8	20.4	64.3	ND	12
4	3	0	25.8	20.2	44.5	4.7	28
5	3	0	65.1	45.4	80.7	ND	43
6	3	0	23.1	20.0	42.0	19.2	16
	3	6	7.4	5.2	10.2	53.0	42
7	4	355	10.3	3.1	18.9	ND	23
8	10	425	25.5	18.2	39.2	15.4	40

*ND = Not Done due to lack of sufficient lymphocytes

Results are the mean of one experiment performed in triplicate

Example 3. Immunotherapy of human ovarian carcinoma in an animal model

In order to investigate the therapeutic effectiveness, MAb-B43.13 was tested in a human-PBL-SCID/BG mouse model. Mice were reconstituted with human-PBL(normal donors) by i.p. injection of 2 to 3x10⁷ PBL/mouse. MAb-B43.13 was administered at 100 µg/mouse in PBS, in different experimental set-ups. An isotype matched control antibody (MOPC21 or MAb-170) and PBS injection served as controls. The ovarian cancer cells NIH: OVCAR-Nu3 were injected i.p.at 1x10⁶

cells/mouse or s.c. at 4×10^6 cells/mouse . Hu-PBL-SCID/BG mice were either immunized before injection of tumor cells, or after small tumors were established (two weeks after transplantation). In another experiment, tumor-bearing mice (s.c.) were injected with MAb-B43.13 two weeks after tumor transplantation, along with PBL .

Antibody injections were repeated twice in 2-week intervals. Functional and cellular characterization of serum and PBL from these mice demonstrated the successful engraftment of a human immune system in those mice.

All three experiments showed that MAb-B43.13 treatment could: a) delay or prevent development of tumors; b) reduce the size of small, established tumors (s.c. tumor injection) or suppress ascites production; c) delay tumor growth when injected prior to tumor implantation and d) prolonged the survival of mice (i.p. tumor injection).

Human tumor infiltrating lymphocytes (TIL) were identified in mice using flow cytometry, which might contribute to the in vivo anti-tumor activity of MAb-B43.13.

At the endpoints of the therapy study, surviving mice from different treatment groups were euthanized. Blood, spleen, tumor, and peritoneal washes were obtained form the measurement of human immunoglobulin as well as flow cytometric analysis of human PBL in mouse tissues. Tumors were also analyzed by immunohistochemistry.

We first determined whether MAb-B43.13 has in vivo anti-tumor activity, when the tumor was localized within the peritoneal cavity (similar to ovarian cancer patients) and of limited size at start of the treatment. NIH:OVCAR-NU-3 tumor cells (CA125 positive), human PBL, and MAb-B43.13 or control antibody (MAb-170) were all injected intraperitoneally. This treatment regimen maximized

the effect of the antibodies on tumor cells. As shown in Figure 8, MAb-B43.13 antibody had preventive effect on ascites development and significantly prolonged the survival of SCID/BG mice bearing i.p. injected tumor cells ($p < 0.01$, Table 6). The development of ascites production was carefully monitored. Approximately two weeks after detection of ascites, mice became sick and died within a few days. Therefore, mice were terminated as soon as they showed signs of illness and/or discomfort. The percentage of surviving mice was plotted against the time after tumor transplantation. [Figure 8 legend: ♦, MAb-B43.13 + PBL; ■, MAb-170 + PBL; ▲, PBS + PBL; •, tumor only]. The patterns of ascites development in the control groups (MAb-170-PBL, PBS-PBL and no treatment) were found to be similar to each other. The survival times of the mice in these control groups were approximately the same.

Table 6

Statistical Analysis of the survival data in MAb-B43.13 treated tumor bearing (i.p.) Human-PBL-SCID/BG mice

Treatment comparison	mean difference	q	p value
No treatment vs. PBS-PBL	-4.1667	0.6411	> 0.05 (NS)
No treatment vs. control MAb-PBL	-9.2333	1.4207	> 0.05 (NS)
No treatment vs. MAb-B43.13-PBL	-35.4	5.4468	< 0.01 (S)
PBS-PBL vs. control MAb-PBL	-5.0067	0.7796	> 0.05 (NS)
PBS-PBL vs. MAb-B43.13-PBL	-31.233	4.8057	< 0.05 (S)
control MAb-PBL vs. MAb-B43.13-PBL	-26.167	4.0261	< 0.05 (S)

The therapeutic studies described above demonstrated that B43.13 antibody

could delay or prevent the development of non-established, presumably dispersed tumor cells intraperitoneally. In order to determine whether MAb-B43.13 has also anti-tumor activity on established tumors, NIH:OVCAR-NU-3 tumor cells were injected s.c. into the flank of SCID/BG mice (4×10^6 cells/mouse) and allowed to grow before start of the immunizations. Approximately one week after tumor cell inoculation, the mice developed palpable tumors. Mice were divided into four groups and underwent different treatments: MAb-B43.13-PBL, MAb-B43.13 alone. MOPC21-PBL and MOPC21 alone. Treatment of tumor-bearing mice with MAb-B43.13 significantly decreased the tumor growth compared to the control groups as evaluated by tumor size measurement ($p < 0.05$). The inhibition of tumor growth rate as measured by tumor size corresponded to that measured by tumor weight. These results indicate that MAb-B43.13 treatment is also efficacious in mice with established tumors (Figure 9).

A human immune system was first established in SCID/BG mice by intraperitoneal injection of human PBL. One day later, half of the PBL-reconstituted mice received MAb-B43.13 and the other half was administered with MAb-170 (i.p. immunizations). One week after PBL reconstitution, all of the mice were injected s.c. with NIH:OVCAR-NU-3 tumor cells. An additional control group of mice received s.c. tumor cell injection without prior administration of PBL or antibody. Figure 10 shows the tumor appearance in mice injected with 2×10^6 tumor cells for various treatment groups. A consistent delay of tumor appearance in MAb-B43.13-PBL group was observed as compared to both control groups. Tumor establishment of 100% was delayed by nine days in both MAb-B43.13-PBL and MAb-170-PBL groups. Since the tumor take in all groups eventually was 100%, The mean tumor size of the different treatment groups over a period of 2 months was measured and compared. Although the mice in the MAb-170-PBL group also showed delay of tumor appearance compared to the group with no treatment, no significant difference in tumor size was observed between these two groups over the

1 experimental period of two months (Figure 11). On the other hand, significantly
smaller tumors were found in the MAb-B43.13-PBL group at all times ($p < 0.01$)
(Figure 11).

**Example 5. Induction of idiotypic network to anti-MUC-1 antibody in
breast cancer.**

6 MUC-1 proteins (polymorphic epithelial mucin) expressed on malignant
epithelium are underglycosylated, which leads to exposure of novel T and B cell
epitopes. An anti-MUC-1 murine clone, AR20.5 was generated by immunization of
mice with CA15.3 antigen, a glycoprotein consisting of an MUC-1 protein
11 carbohydrate and characterized for its binding specificity to CA15.3 and MUC-1
tandem repeated core peptide by ELISA and to MUC-1 transfectoma by FACS
analysis. Injection of MAb-AR20.5 (Ab1) conjugated to KLH into mice carrying
MUC-1 transfectoma resulted in anti-idiotypic antibody (Ab2) (Figure 12) and anti-
anti-idiotypic antibody (Ab3) production (Figure 13). A minimum of four injections
at a dose of 50 μg /mouse was needed to obtain the measurable humoral response.
16 The Ab2 and Ab3 levels reached their peak after six injections. The anti-idiotypic
antibody (Ab2) competed with the native antigen, CA15.3. T-cells proliferation
studies showed specific response to the injected antibody and CA15.3 indicating the
presence of idio type specific T-cells (T2) and anti-idiotypic specific T cells (T3). See
Figure 14. These results encourage us to use such antibodies for immunotherapy of
21 cancer by generating surrogate antigen via Ab1 injections.

In addition, a breast tumor model was developed using a human MUC-1
gene transfected mouse mammary carcinoma, 413BCR. Groups of mice were
treated with Ar 20.5-KLH or human immunoglobulin conjugate, and compared to
appropriate positive control (liposomal MUC-1) and negative control (murine
26 immunoglobulin). Immunizations were performed twice before or after tumor

1 implantation at weekly intervals. The tumor volumes were measured weekly and the growth rates assessed. A significant tumor reduction was observed in mice treated with AR 20.5-IgG conjugate compared to other groups. See Figure 15.

Example 6.

6 A composition according to the invention was produced against CA 19.9 (SLe^a), an excellent marker for pancreatic cancer (87%), gastric cancer (68%), and colo-rectal cancer (50%).

The binding agent was AR 44.6, an IgG3 antibody that binds strongly to CA 19.9, and has been shown to mediate tumor killing through CDC *in vitro*.

11 Approximately 10⁴ chromium labeled SW 1116 (2200 CPM) were incubated with different concentrations of AR44.6, AR44.4, NS1116, AR18.4, and unspecific mIgG3 (20 µg/mL to 0.0025 µg/mL). The antibodies were incubated for 45 minutes at 4°C. In the treatment groups incubated with HAMA, the antibodies were washed twice with medium and incubated with 1 µg/mL of HAMA for 45 minutes at 4°C. All plates were washed and effector cells (fresh collected human PBLs) or fresh human serum (20% in medium) were added and incubated for four hours. The cytotoxic index (C.I.) was then calculated. Paired T test was used to analyze each concentration.

Figure 16 shows the results obtained for AR 44.6, AR 44.4, and unspecific IgG3 mediated CDC (with or without human anti-mouse antibodies, HAMA).

21 Figure 16 shows that AR 44.6 and AR 44.4 are extremely effective in complement-mediated cytotoxicity. Such cytotoxicity is increased in the presence of HAMA. The anti-tumor effect of AR 44.6 was also analyzed in SCID/BG mice reconstituted with human PBL. Figure 17 shows a reduction in tumor volume as a result of the binding agent and the binding agent/antigen complex.

Example 7. PSA directed immunotherapy of prostate cancer (Production of AR47.47)

Prostate specific antigen (PSA) represents an attractive target for the immunotherapy of prostate cancer. This glycoprotein is almost exclusively synthesized by the prostatic gland and is currently used for the diagnosis and monitoring of prostate cancer patients. However, since PSA is recognized as a self-antigen, it is essential for effective immunotherapy to develop innovative strategies capable to trigger the immune system and induce a protective immunity against PSA expressing cells. This example demonstrates the use of an antibody to elicit an anti-idiotypic cascade associated with an antigen specific anti-tumor immune response. A large panel of anti-PSA monoclonal antibodies have been produced in our laboratory and these antibodies were evaluated for their potential therapeutic efficacy against prostate cancer. We have demonstrated that the immunization of mice with a selected anti-PSA antibody can induce a specific immunity against PSA itself. These results therefore emphasize the potential use of anti-PSA antibodies for the immunotherapy of prostate cancer.

Hybridoma clones secreting anti-PSA antibodies were produced by fusion of the murine myeloma cells Sp2/O with the splenocytes of a Balb/c mouse immunized with human PSA. An exemplary clone, AR47.47, binds to an epitope of PSA corresponding to amino acid sequences 139-163 of the PSA molecule (see Figure 18).

The first criteria of selection used to identify the anti-PSA antibody was the ability of this antibody to interact with circulating PSA. Circulating PSA is found either in a free form or complexed to anti-proteases such as α -anti-chymotrypsin and α 2-macroglobulin. To screen for clones we used three different forms of PSA: free PSA; PSA complexed to α -anti-chymotrypsin (PSA-ACT); and free PSA non complexing to α -anti-chymotrypsin (PSA-nc). Free PSA corresponds to PSA

1 directly purified from human seminal fluid. Co-incubating free PSA with purified
ACT results in the formation of PSA-ACT and PSA-nc. PSA-nc can be separated
by gel filtration chromatography. It is believed that PSA-nc may represent the free
form of PSA present in the circulation. Complexing of PSA with α 2-macroglobulin
results in the total encapsulation of PSA. As a consequence, this form of PSA is no
6 longer detectable by monoclonal anti-PSA antibodies. We therefore did not use this
form of circulating PSA for the screening.

PSA belongs to the kallikrein family and a high degree of structural
homology is found between PSA and the kallikreins HK1 and HK2. The absence of
cross reactivity of the anti-PSA antibody with kallikrein isolated from human
11 plasma was used as second criteria for selection.

The hybridoma clone AR47.47 responded to the criteria described above, a
strong immunoreactivity was observed with the three forms of PSA used for the
screening whereas no cross reactivity was observed with human plasmatic
kallikrein. The hybridoma clone AR47.47 was cloned twice by limiting dilution and
16 the second generation clone AR47.47R6R6 was chosen for further studies. Clone
AR47.47R6R6 was adapted to standard medium (RPMI 10% FBS) and a cell bank
was formed. The absence of mycoplasma contamination was verified by using the
Boehringer Mannheim mycoplasma test. Clone AR47.47R6R6 has been deposited in
the American Type Culture Collection, and has received Accession No. H-B 12526.

21 We have studied in DBA mice whether the immunization with a binding
composition according to the invention (AR47.47) can result in the induction of a
specific PSA immunity via the idiotypic network (i.e. induction of Ab3 antibodies).
Anti-PSA antibodies (Ab3) could be detected in the serum of animals immunized
with AR 47.47, a minimum of two injections of AR 47.47 was required for Ab3
26 production. No reactivity towards PSA was detected for the control groups (mice
immunized with an isotype matched control antibody not related to PSA and mice

1 receiving PBS injections).

AR 47.47 is directed towards a PSA epitope comprised between the sequence 139-163 of the PSA molecule. The anti-PSA antibodies produced by AR 47.47 immunized mice can specifically interact with the PSA peptide 139-163. We can therefore conclude that at least part of the Ab3 produced are identical in term of specificity to AR 47.47. These results demonstrate that the immunization with AR 47.47 can induce a specific anti-PSA immunity in the host (Figure 18).

Example 8. Anti-idiotypic induction of PSA immunity in mice

We have studied in mice whether the immunization with anti-PSA antibodies can induce a specific immunity against PSA via activation of the idiotypic network. The goal of this experiment was to demonstrate that the immunization of mice with anti-PSA antibodies (Ab1) can stimulate the immune system to generate anti-idiotypic antibodies (Ab2 = surrogate antigen), and anti- anti-idiotypic antibodies (Ab3) capable of reacting with the original antigen.

We used for these experiments a commercially available antibody as a model anti-PSA antibody (RLSD09; ATCC HB-8525). The purified antibody was conjugated to Keyhole Limpet Hemocyanin (KLH) to enhance its immunogenicity. The anti-PSA antibodies conjugated to KLH were still capable of binding to PSA, indicating that the idiotype of the antibodies were not masked by the conjugation procedure. B43.13 antibody, a mouse monoclonal antibody of the same isotype as the PSA antibody (IgG1) was used as the control. B43.13 antibody is specifically directed against the CA125 ovarian tumor antigen and does not cross react with PSA. In addition we verified by FACS analysis that the B43.13 antibody does not bind at the cell surface of Line-1-PSA or P81 5-PSA.

Mice were subdivided into three groups of five mice each. The first group of

1 mice was immunized with anti-PSA antibody conjugated to KLH. The second group of mice was immunized with the control B43.13 antibody conjugated to KLH. The third group of mice received PBS injection. Injections were performed i.p. at 10 days intervals with complete Freund adjuvant for the first injection and incomplete Freund adjuvant for the second injection.

6 Ab2 is a surrogate antigen capable of mimicking the PSA epitope recognized by the injected anti-PSA antibody. A competitive inhibition assay was established to measure the serum level of Ab2. This assay was performed 5 days after the second injection. An inhibition was observed after incubation in the presence of mouse sera from mice immunized with anti-PSA antibody, but not when sera from mice immunized with control antibody or PBS were used. These results indicate that the immunization of Balb/c mice and DBA mice with the anti-PSA antibody can induce the formation of anti-idiotypic antibody (Ab2) capable of mimicking PSA.

Example 9. Effect of Anti-PSA immunization on tumor development

16 We have studied in Balb/c mice whether the immunization with anti-PSA antibodies can protect the animals against a subsequent tumor challenge. Balb/c mice were divided into 3 groups of 5 mice each. The first group was immunized with anti-PSA antibody RLSD09 conjugated to KLH, the second group was immunized with control antibody B43 conjugated with KLH, the third group received PBS injections. A total of 4 injections were given for each group using 50 μ g of antibodies for each injection. The tumor cells Line-1-PSA were injected intravenously between the third and fourth injections. Nineteen days after tumor inoculation, the mice were sacrificed, the number of tumor foci in the lungs and AB3 levels in the serum were determined.

21 The tumor burden in the group of mice immunized with anti-PSA mAb was

1 considerably lower compared to the group of mice immunized with control antibody. Of particular interest is the demonstration, in the group of mice immunized with anti-PSA mAb, of a negative correlation between Ab3 levels and the number of tumor foci in the lungs.

Example 10. Anti-inflammatory composition.

6 To test for the effectiveness of a composition containing a binding agent in treating inflammation, a double blind experiment was performed on 18 Sprague Dawley rats (weight about 450g) divided into 3 groups (8 rats in each group).

11 The first group was vaccinated with KLH conjugated IgM antibody specific for a carbohydrate ligand on leukocytes (250 μ g/rat, i.p.). The second group was vaccinated with KLH conjugated IgM antibody with no binding to the same ligand (250 μ g/rat, i.p.). The third group was a control group, and received no vaccination.

16 Inflammation was induced by injecting 1% carrageenan in 0.9% NaCL (type IV), in the rat right hind paw (0.5 ml/rat). Observation of paw edema by water displacement measurement and caliper measurement.

The inhibitory effect of AR18.4 antibody on inflammation was clinically different from the control group and control IgM antibody group.

The results of these experiments are shown graphically in Figure 19.

Example 11. Photoactivation increases immunogenicity

21 Normal, healthy, Sprague-Dawley rats were used. Animals were randomly grouped (4 per group) to receive four different doses (5 μ g, 10 μ g, 25 μ g and 50 μ g)

1 of MAb 43.13. Pre-injection blood samples were drawn prior to initiation of the
injection schedule. Each rat received the appropriate dose of MAb diluted in sterile
0.01 M phosphate buffered saline intravenously. A second study group received 20
µg of each MAb preparation with or without Incomplete Freund's Adjuvant (IFA).
6 Blood samples were taken just prior to the dose injection at 0, 21, 42, 63 and 77
days.

MAb-B43.13 is a murine IgG, reactive with CA 125. Antibody preparations
consisted of MAb-B43.13 in the native form or in a UV-exposed form (e.g.,
photoactivated). Native MAb was diluted from a stock concentration of 5 mg/mL
with 0.01 M phosphate buffered saline to doses of 5, 10, 25 and 50 µg/100 µL. UV
11 exposed MAb was reconstituted from the lyophilized form with 0.01 M phosphate
buffered saline (2.2 mg/0.47 mL) and diluted to obtain the same doses as for the
native MAb.

An assay was developed to measure the rat anti-mouse response in the serum
of the injected animals. Anti-isotype rat anti-mouse antibodies were measured using
16 an ELISA plate coated with an isotype matched control antibody, MOPC 21.
Samples were diluted 1/100, allowed to react with the coated antibody, washed, and
bound antibody detected using peroxidase conjugated goat anti-rat IgG (H + L)
with ABS substrate. Unknowns were read off a standard curve generated using a
commercial rat anti-mouse antibody.

21 The results of the rat anti-mouse (RTAMA) analysis of sera from the various
groups of rats injected with native and UV exposed MAb-B43.13 is shown in Table
7 and Table 8. The immunological response to the preparations is expressed in
terms of the number of responders in each group, with the numerical cut-off defined
in the tables. This value (mean of all pre-injection samples (blanks) + 3 S.D.)
26 ensures that a true positive response is measured and the results are unlikely to be
due to assay variation. The tabulation of responders is probably more meaningful

given that the fluctuation of the magnitude of response can be very large and therefore, hinder interpretation.

Table 7

**ANIMAL RESPONSE* TO INTRAVENOUS INJECTION OF NATIVE
AND UV EXPOSED MAb-B43.13 PREPARATIONS**

Sampling Time	Preparation	Number of Responders			
		5 µg	10 µg	25 µg	50 µg
Pre-injection (blank)	Native	NA**	NA	NA	NA
	UV exposed	NA	NA	NA	NA
Day 21	Native	0	0	0	0
	UV exposed	2	3	1	1
Day 42	Native	0	1	0	1
	UV exposed	2	3	4	3
Day 63	Native	1	3	3	3
	UV exposed	2	4	3	4
Day 77	Native	2	2	2	1
	UV exposed	3	4	4	4

* Number of animals responding in a group of four (RTAMA values \geq pre-injection sample mean + 3 S.D.)

** NA = Not Applicable

The data tends to confirm that the response to the UV exposed MAb-B43.13 occurs earlier (after only one injection) as shown by the greater number of responders at all dose levels in the Day 21 groups.

Furthermore, at all other time periods (and after multiple injections), the

proportional response of each group given intravenous UV exposed MAb-B43.13 is greater. It may be suggested that the response is sustained longer for UV exposed MAb-B43.13 since the native MAb-B43.13 appears to show a reduced response rate from Day 23 to Day 77. Actual values of increased response at day 77 are shown in Table 8.

Table 8

TOTAL AND AB₂ INDUCTION IN RATS INJECTED WITH NATIVE OR UV-EXPOSED MAB-B43.13

	TOTAL IMMUNE RESPONSE (mean \pm S-E)	Ab ₂ RESPONSE (mean \pm S-E)
Native Mab — B43.13	38.47 \pm 2.99*	18.77 \pm 8.23
UV-exposed Mab — B43.13	1608.67 \pm 369.39*	87.27 \pm 45.11

n = 3

* p = 0.0496

Example 12. Protein modification as a result of UV exposure

The final chemical species present after photoactivation are specific for a given set of exposure conditions and the composition of the matrix solution (as described above). For simple polypeptides containing any of the three primary UV absorbing (UV-B) amino acids (cystine, tryptophan, tyrosine) the consequences of UV exposure can lead to amide bond cleavage, disulfide bond cleavage, alteration of absorbing amino acids and alteration of adjacent or close proximity amino acids. These changes are brought about by direct photoionization or photoexcitation and indirectly by radical formation from other constituents. The nature and extent of

1 these modifications is highly dependent on the chemical reactivities of the species generated and other constituents reactive tendencies or stabilizing/quenching capabilities. For this size of molecule any alteration generally results in dramatic changes in biological function.

6 These same reactions can take place in larger proteins, however secondary and tertiary structural elements present differing substrates for UV exposure in spite of similar amino acid sequences. Therefore, the hydrophobic/hydrophilic nature and proximal amino acids from distant chain sequences as a result of folding alter the micro-environment and therefore influence the degree and nature of the modification, in addition to other constituents issues stated above. Given the
11 predominance of the tryptophan absorption profile in this UV band width, it is thought to be the primary site of the initial photoactivation process, but direct action on cysteine and tyrosine are also viable.

16 The mechanism for indirect amino acid modifications has been proposed as local hydrated electron generation or direct energy transfer from the primary absorbing site. The primary observed changes for large proteins focus on measurable chemical/biochemical changes such as absorption and fluorescence determinations of aromatic amino acids which relate to global modifications. Individual amino acid alterations be detected in this group of proteins where
21 sulfhydryl content can be determined as evidence of cysteine disulfide cleavage and/or where a critical amino acid for function is involved. For smaller proteins amino acid hydrolysis and complete quantitation can be performed. The primary concern for functional large proteins, such as enzymes, receptor, or antibodies, is therefore not specific amino acid modification but the consequences of any change on their biological function, and has invariably been described as loss of enzyme
26 function, receptor recognition, or antigen binding.

Example 13. UV Exposed B43-13/CA125 antibody/antigen complex Produces Better CA125 Specific Cellular immune Response and better humoral response.

Better cellular immune response was observed when the UV exposed antibody was presented in association with the antigen to T-cells. Thus, macrophages isolated from mouse peritoneal cavities were stimulated with native B43.13 or UV exposed B43.13 in association with CA125 and presented to CA125 specific mouse T-cells isolated from mice injected with CA125. Control experiments included stimulation of the macrophages without the antigen. When the proliferation of T-cells as monitored by [³H] - thymidine uptake was followed, optimal stimulation index was observed in macrophages stimulated with UV exposed B43.13 - CA125 complex. The results are summarized in Table 9 below.

Table 9

STIMULATING AGENT ¹	STIMULATION INDEX ²
CA125	2.76
Native MAb — B43.13	3.98
UV-exposed MAb — B43.13	3.31
Native MAb — B43.13 — CA125	4.71
UV-exposed MAb — B43.13 — CA125	5.28

1. 1 µg/ml of the antibody and 100 Units/ml CA125 were used.
2. Mean of three individual experiments done in triplicate.

Example 14. Immunophotodynamic therapy

An immune competent mouse model is available for the MUC-1 system. The MUC-1 transfectant 413 BCR forms tumors (subcutaneous or intravenous) in BALB/c or CB6F1 mice. The BALB/c animal model was used to test HBBA-R2-SL, HBBA-R2 SIL with AR20.5 and B43.13 (SL = stealth liposome; SIL = stealth immunoliposome). The model has the advantage that the bystander effect of the immune system can be analyzed. Help from the immune system, especially from macrophages, has been reported to augment the immune system for the outcome of PDT and as necessary for obtaining complete response rates. BALB/c mice for injected with $2-2.5 \times 10^6$ 413BCR cells into the right flank (s.c.).

Tumors appeared after 7-10 days. When tumors reached a diameter of about 5 mm, hypocrellin formulations were injected iv. at 1 mg/kg. Two hours post injection of HBBA-R2, light treatment was performed as described for HBEA-R1 at 40 J/cm^2 ($> 600 \text{ nm}$). Mice were followed by measuring tumor size. When tumor size reached 4-times pre-treatment volume, mice were sacrificed. Tumors were followed for 2 months and survival curves were calculated, plotted and compared to the light-only treatment group.

For stealth immunoliposome compositions, two different antibodies were used: AR20.5, which binds to 413BCR cells, and B43.13 as a negative control. Tumors were measured every second day in three dimensions. When tumors reached 4 times pre-treatment volume, mice were sacrificed. Mice treated with light only or drug only were used as control.

Immunoliposomes with AR20.5 showed complete cure in the presence of light (Figure 20). The non-specific immunoliposomes, coupled with B43.13 show therapeutic efficacy comparable to SL. The HBBA-R2-SIL [AR20.5] also showed improved survival in the dark, compared to mice treated with light only or HBBA-SIL[B43.13] plus light. These results suggest a therapeutic effect of AR20.5 in this

1 model and underline the importance of combined therapy using PDT and antibody vaccine.

6 For all formulations tested, immunoliposomes specific for the tumor showed the best therapeutic effect. This was also reflected when tumor volumes were used for comparison. The reason for the enormous differences between SL and SIL is not yet completely understood. The data suggest that immunoliposomes might cause an immune response in BALB/c mice that can help killing the tumor. From the biodistribution data we know that HBBA-R2 uptake at the tumor is slightly higher with SIL compared to SL.

Example 15.

11 The goal of this study was to construct a fusion protein of scFv linked to biotin mimetic sequence (BMS), and express in the *P. pastoris* expression/secretion system by using cancer-therapeutic monoclonal antibody MAb B43.l3 which selectively recognizes a unique epitope of CA125 expressed on ovarian carcinomas. The use of scFv is advantageous in CA125 assays for the serum samples, from which patients were treated with a MAb B43.l 3-based vaccine, even in presence of HAMA. Two constructs of scFv derivatives with additional C-terminal extensions containing c-myc/BMS (pDL-5), and spacer/BMS (pDL-9), were designed. The scFv without BMS sequence was used as a negative control molecule in biotin/streptavidin assays.

21 It has been generally believed that the recombinant proteins expressed and secreted from the recombinant *P. pastoris* cells retains their biological activities. In order to demonstrate that the scFv proteins have their intrinsic binding activities, competitive radioimmunoassay (RIA) experiments were carried out. We found that the purified scFv samples isolated from pDL-5 and pDL-9-transformed cells showed

1 positive binding activity in RIA, in comparison with the control scFv and their
parental MAb B43.13.

6 The design of biotin mimetic sequence was based upon the results obtained
from screening of cyclic peptide phage libraries to identify the ligand that bound
Streptavidin with high affinity. The biotin-Streptavidin interaction is widely used in
immunoassays to enhance the detection signal. To demonstrate that the fusion
proteins exhibit biotin mimetic conformation and to compare the biotin detection
between these two constructs (pDL-5 and pDL-9), the ELISA experiments with
direct CA125 binding and "sandwich" CA125 binding were carried out. One of the
reasons might be that linear epitope sequence of c-myc represented a rigid structural
conformation between the scFv and BMS motif. Therefore, it may disturb the loop
structure of BMS or the binding of BMS to Streptavidin.

Example 16.

16 Three derivatives of scFv with additional C-terminal extensions containing
mouse and human tuftsin (pDL-6 and pDL-11), or a control sequence (pDL-10),
were designed. To construct plasmids pDL-6, pDL-10, and pDL-11, DNA
oligodeoxyribonucleotides

(5'-GAATTCTGGAGGTGGTACCCAGCCTAGGTAGC-3',

5'-GAATTCAGCTGGAGGTGGTGGATGTGC-3', and

5'-GAATTCTGGAGGTGGTACCAAGCCTAGGTAGC-3')

21 coding for the amino acid sequences N-SerGlyGlyGlyThrGlnProArg-C,
N-SerAlaGlyGlyGlyGlyCysAla-C, and N-SerGlyGlyGlyThrLysProArg-C, were
used by inserting fragments in *Eco*RI and *Eag*I sites of pPIC-B43. The plasmid
DNAs were transformed into competent GS115 cells by electroporation and the

1 resulting transformants were selected on histidine-deficient media. All positive clones obtained were isolated, cultured in induction media, and analyzed for protein expression in SD S-PAGE followed by Commassie staining. The scFv-tuftsins proteins were produced in minimal media to simplify some downstream protein purification process.

6 In order to evaluate the anti-idiotypic response, six to 8-week-old BALB/c mice were immunized with 50 μ g scFv-tuftsins subcutaneously (Day 0). Two weeks later the mice were received 25 μ g of scFv-tuftsins intraperitoneally. The serum of mice was collected on Day 7, 14 and 21.

11 The anti-idiotypic antibody production were detected by enzyme-linked immunosorbent assay (ELISA). Briefly, chimeric B43.l3 were coated to a solid surface and then blocked by 3% BSA/PBS. The chimeric B43. 13 were incubated with serum samples for 1 h and then incubated with goat anti-mouse H+L-HRPO for another hour followed three times wash with Tween 20/PBS. A color reaction was developed by adding 50 μ l of substrate solution. Absorbance was read at 405nm. 16 The same procedure was applied to detect anti-anti-idiotypic antibody (Ab3) production except CA125 was coated to ELISA plate at the beginning.

21 The data shows that it is possible to detect both Ab2 and Ab3 in the serum samples and this indicates that scFv-tuftsins retained the idiotype immunogenicity which could trigger humoral immune response in mice. We found that the mice immunized with scFv-tuftsins started to show strong anti-idiotypic antibody (Ab2) production after day 20 post the first immunization. However, the anti-anti-idiotypic antibody (Ab3) production appeared earlier, peaking around day 15. This indicates that induction of an idiotype network response might be an important effector mechanism in MAb-based therapy.

Example 17.

The murine monoclonal antibody AR18.4 is a candidate for the development of an anti-gastrointestinal cancer compound. MAb-AR 18.4 binds to tumor antigen CA19.9, a Sialyl Lewis^a antigen which is now generally recognized as one of the most important tumor-associated markers for gastro-intestinal cancer. An approach of chimerization of antibody is to construct mouse-human antibody, which is composed of mouse variable region and human constant region, by using recombinant DNA technology. Most reports demonstrate the chimeric antibody is able to retain the same specific binding activity to the antigen as its parental mouse antibody, but avoid the human anti-mouse antibody (HAMA) response with *in vivo* applications.

Experimental Strategies:

cDNA isolation of V-genes: RT-PCR experiments were carried out to isolate antibody variable genes using specific primers. The cDNAs were then cloned into cloning vector pBluscript for DNA sequencing.

Chimeric Antibody Construction: chimeric clones of PAH-18.4H8PCRII#8 and PAG-18.4L20PCRII#19 was obtained by ligating PAG4622-18.4LPCRII and PAH46.6-18.4HPCRII as expression vectors and inserts were obtained from PBKS-18.4L20PCRII#14 and PBKS-18.4HPCRII #19. Chimeric clones were used for transfection of SP2/0 cells. To obtain the most efficient method for co-transfection of these cells control plasmid pSV- β gal DNA was used as a positive control plasmid to obtain the optimal conditions for transfection into cells.

Transfection: both methods of transfection showed successful transfection efficiency. Lipofectamine causes some cell death but most cells (80%) of cells that stay alive are transfected. In electroporations method cells transfection efficiency was high and cells that were transfected were growing into colonies which

1 contained the new control plasmid. After establishing optimal conditions for
transfection of SP2/0 cells co-transfection of SP2/0 cells with PAH-18.4 and PAG-
18.4 was done.

6 Lipofectamine method: 2ug of each DNA plasmid was used. The same
protocol was mentioned above was followed. 24 hours after transfection, cells were
harvested from 6-well plates and cells were seeded in 96-well plates with cell density
of 1.0×10^4 cells/well. After overnight incubation at 37°C , selection media was
added to each well in 1:1 ratio. Selection media includes $1 \mu\text{g}/\mu\text{l}$ of mycophenolic
acid and 5mM histodinal, 7.5 PH which was adjusted using NaOH. Selection media
was changed every 3 days and cells were in selection media for 12 days

11 Electroporation method: $20 \mu\text{g}$ of each DNA plasmid was used. The same
method as mentioned above was used for transfection. Cells were plated into 96-
well plates after electroporation. with 1×10^4 cells/well density. 24 hours after
transfection selection media was added to cells. Cells were kept under selection
media for 12 days and media was changed every 3 days.

16 To determine whether transfection has occurred supernatant of transfected
cells were used for ELISA to assay the production of desired chimeric protein. CAI
9.9 was used to coat the plates and they were blocked by 3% BSA. For primary
antibody tissue culture supernatant was used and for secondary antibody rabbit anti
human (Fab'2) IgG (H + L) was used. Assay from ELISA gave positive results for
21 production of desired product.

Example 18. Construction and characterization of single chain antibody

The MAb B43.13 variable domain sequences were PCR-amplified using
sequence specific primers, and engineered into a cloning vector with scFv
orientation of V1-linker-Vh. The DNA fragment coding for the scFv was then

1 subcloned into *P. pastoris* vector, pPIC-9 with aF secretion signals, resulting in
recombinant plasmid pPIC-B43.13. One derivative of pPIC-B43.13 with additional
C-terminal extensions containing one cysteine (pDL10) was designed to form a
disulfide bridge. Therefore, the antigen binding activity can be enhanced by increase
of avidity. To construct plasmids pDL10, DNA oligodeoxyribonucleotides (5'-
6 GAATTCAGCTGGAGGTGGTGGATGTGC-3') coding for the amino acid
sequences, N-SerAlaGlyGlyGlyGlyCysAla-C were used by inserting fragments in
EcoRI and *EagI* sites of pPIC-B43.13.

The plasmid DNAs were transformed into competent GS115 cells by
electroporation and the resulting transformants were selected on histidine-deficient
11 media. After screening for integration at the correct loci, (i.e. colonies can grow on
a -his/ + glycerol plate but grow slowly on a -his/ + methanol plate), all positive
clones obtained were isolated, cultured in induction media, and analyzed for protein
expression in SDS-PAGE followed by Coomassie staining, as we described
previously (Luo et al., 1997). The protein samples were dialysed against PBS and
16 concentrated using Centricon 10 filter (Amicon, Danvers, MA).

Purity of scFv-pDL10 were analyzed by SDS-PAGE under reducing
condition. CA125-binding specificity was determined using a ELISA in which
microtiter plate wells were coated with CA125, CA15.3 (a human breast cancer
antigen), or CA19.9 (a human colon cancer antigen). The bound single chain
antibody was detected by peroxidase-labeled goat ant-mouse H and L (Southern Bio.
21 Associ.) For 1 hour at room temperature. Following three washes, 50 μ l of ABTS
substrate solution was added. The absorbance was measured at 405nm.

Single chain Fv containing poly(lactic-co-glycolic acid) microspheres were
prepared by a double-emulsion technique with some modifications (Uchida et al.,
26 1994). Na¹²⁵I labeled scFv-pDL10 was used as a tracer to determine the loading
efficiency. Briefly, scFv-pDL10 (1.5 mg) and Na¹²⁵I-scFv-pDL10 (0.4 μ g) in PBS was

1 mixed with 500 μ l of chloroform containing 100 mg PLGA 50/50 (Lactel). The
mixture was sonicated for 15 s using a sonicator homogenizer (Heat System, New
York). The resulting emulsion was added to 2 ml of 9% poly(vinyl alcohol) (PVA,
Aldrich, USA). Emulsification was continued by sonicate on for 1 min. The
emulsion was transferred to 8 ml of 9% PVA and stirred for 2 hours for evaporation
6 of the chloroform. Microspheres were recovered by centrifugation (15 min, 15000
rpm) and have washed with distilled water and freeze dried for at least 24 hours.

BALB/c female mice 6-8 weeks of age were used in all in vivo experiments.
The immunization groups included five groups: 1) immunized with PLGA
microspheres, 2) immunized with scFv-pDL10, 3) immunized with scFv-pDL10
11 formulated in PLGA microspheres, and the other two groups immunized with the
mixture of formulated scFv-pDL10 and GM-CSF or TNF- α . After collection of
preimmune serum samples, groups of 4 mice received two subcutaneous
immunizations on day 0 and day 14, followed by two intraperitoneal
immunizations on day 21 and day 28. The dose for immunization was 10 mg of the
16 microspheres for s.c., 5 mg for i.p.. For other groups received no microspheres, the
dose of scFv-pDL10 matched the amount formulated. The cytokines were purchased
from Southern Bio. Associ. (USA) and were given to mice at a dose of 0.1 μ g per
day. Tail vein blood samples were taken periodically into Microtainer tubes (Becton
Dickinson, USA) and frozen at -80°C until assay.

21 Example 19 . Dose

Those with skill in the art recognize that the administered dosage can vary
widely based on a wide set of different circumstances. The following provides
preliminary dosage guidelines.

Retrospective analysis of more than 100 patients who have been injected up

1 to ten times with a 2mg dose of MAb-B43.13 indicated that some of these patients experienced: a) an unusual course of their disease, characterized by unexpectedly long survival times; and b) no significant adverse reaction or toxicity.

6 Immunological studies were conducted to understand and evaluate the *in vivo* mechanism of action of MAb-B43.13. These studies indicated that the extent of anti-idiotypic induction in patients injected with a 2mg dose of MAb-B43.13 was unrelated to the number of injections or the clinical stage of their disease. However, anti-idiotypic induction is dependent on the levels of the circulating CA 125 present in the patient's sera. Additional experiments demonstrated that the injection of MAb-B43.13 into patients with measurable serum CA 125 led to the formation of antigen-antibody complexes, resulting in antigen epitope presentation and antigen-specific humoral and cellular response to the tumor.

11 These studies indicate that an effective dose requires only enough antibody to optimally deliver and present all possible circulating CA 125 antigen to the immune system. *In vitro* studies indicated that 1 ng of MAb-B43.13 can bind 10 units of CA 125. Assuming 40 mL of plasma per kg of body weight, the injection of 2 mg of MAb-B43.13 into a 60 kg patient can bind approximately 8333 U/mL of CA 125 in serum. Since all of the ovarian cancer patients tested to date have had far less than 8333 U/mL of CA 125 in their serum, an injection of 2 mg of MAb-B43.13 is more than sufficient to induce the required immune response. Additionally, in patients that received radiolabeled MAB-B43.13 for immunoscintographic confirmation of the disease, the results of imaging were excellent in spite of high serum CA 125, suggesting that there is excess MAB-B43.13 for specific tumor uptake.

26 Furthermore, multiple injections at selected intervals appear to provide optimal benefits to patients, since CA 125 is generated throughout the course of the disease.

1 Finally, the retrospective analysis showed that the 2 mg dose appears to have
therapeutic efficacy; none of the patients (> 100) have developed any serious side
effects or adverse reactions. If the total HAMA response is an indication of anti-
idiotypic induction, a 2 mg dose generates significant levels of anti-idiotypic
antibodies to produce the desired therapeutic benefit. Multiple injections of 2 mg of
6 MAb-B43.13 at selected intervals appears to maintain the anti-idiotypic antibodies at
the desired therapeutic level without causing any isotypic HAMA-induced toxicity.

A range of effective doses or a therapeutically acceptable amount of MAb-
B43.13 therefore includes, but is not limited to, 2 mg.

While the present invention has been described in some detail by way of
illustration and example, it should be understood that the invention is susceptible to
various modifications and alternative forms, and is not restricted to the specific
embodiments set forth. It should be understood that these specific embodiments are
not intended to limit the invention, and the intention is to cover all modifications,
equivalents, and alternatives falling within the spirit and scope of the invention.

1

We claim:

1. A method of altering the immune response against an antigen comprising administering a composition comprising a binding agent, said binding agent induces the production of anti-idiotypic antibody;

permitting said binding agent to specifically bind to a soluble antigen;

6

forming a complex between the binding agent and the antigen, said complex being capable of altering the immune response against the antigen.

2. The method of claim 1 wherein administering a composition comprising a binding agent includes a binding agent selected from the group consisting of one member of an immunologic pair; an antibody; a monoclonal antibody; an antibody fragment; a single chain antibody; a humanized antibody or fragment; a chimera antibody or fragment; a peptide; and a protein.

3. The method of claim 1 wherein the soluble antigen is associated with a human disease or condition.

4. The method of claim 3 wherein the human disease or condition is selected from the group consisting of cancer; tumor; drugs of abuse; multiple sclerosis; allergy; human immunodeficiency virus; bacterial infection; autoimmune diseases; human viruses; and asthma.

16

5. The method of claim 4 wherein cancer is a cancer selected from the group consisting of breast, ovarian, prostate, and gastro-intestinal cancers.

1

6. The method of claim 1 wherein the antigen is a multi-epitopic antigen.

7. The method of claim 1 wherein the binding agent induces an immune response.

8. The method of claim 1 wherein forming a complex between the binding agent and the antigen comprises exposing a previously inaccessible epitope.

6

9. The method of claim 8 wherein inducing an immune response includes producing an anti-idiotypic antibody that binds to said epitope.

10. The method of claim 7 wherein the immune response is a cellular response.

11. The method of claim 7 wherein the immune response is a humoral response.

12. The method of claim 7 wherein the immune response is a cellular and humoral response.

13. The method of claim 10 wherein the cellular response includes producing a T-cell that binds to the binding agent or the binding agent/antigen complex.

16

1 14. The method of claim 11 wherein the humoral response includes
producing an anti-anti-idiotypic antibody to an anti-idiotypic antibody to the binding
agent.

6 15. The method of claim 1 wherein administering a composition comprises
administering a composition that includes at least one of a photodynamic agent; a
binding agent - photodynamic agent complex or conjugate; one or more adjuvants;
one or more excipients; one or more stabilizers; one or more imaging agents; one or
more buffering agents; one or more dispersing agents; one or more effectors; one or
more immunoadjuvants; one or more radionuclides; one or more toxins; and one or
more enzymes.

11 16. The method of claim 1 wherein the binding agent and the binding agent-
antigen complex are immunogenic.

17. The method of claim 1 wherein administering a composition comprising
a binding agent includes administering a binding agent that specifically binds to a
multi-epitopic antigen.

16 18. The method of claim 1 wherein administering a composition comprising
a binding agent comprises administering a binding agent that has been activated.

19. The method of claim 18 wherein administering a binding agent that has
been activated comprises administering a binding agent that has been exposed to
radiation.

1 20. The method of claim 1 wherein administering a composition comprising a binding agent comprises administering a native antibody.

 21. The method of claim 18 wherein the binding agent has been exposed to UV radiation.

6 22. The method of claim 1 wherein the binding agent/antigen complex or parts thereof is an immunogen.

 23. A method for inducing the production of idiotypic antibodies in vivo comprising administering a composition comprising a binding agent and at least one of the following components: at least one of a photodynamic agent; a binding agent - photodynamic agent complex or conjugate; one or more adjuvants; one or more excipients; one or more stabilizers; one or more imaging agents; one or more buffering agents; one or more dispersing agents; one or more effectors; one or more immunoadjuvants; one or more radionuclides; one or more toxins; and one or more enzymes;

11 said binding agent comprising a binding agent that induces the production of an anti-anti-idiotypic antibody.

16 24. A method for treating cancer comprising:

 contacting a tumor-associated antigen expressed in the host with a composition comprising a binding agent that specifically binds to a single epitope on the tumor-associated antigen;

1 allowing the binding agent to bind to the antigen to form a binding agent-antigen complex; and

allowing a host immune response to said complex.

25. A method for eliciting an immune response comprising

6 contacting a multi-epitopic antigen expressed in the host with a composition comprising a binding reagent that specifically binds to a single epitope on a tumor-associated antigen; and

allowing the binding reagent to bind to the antigen to form a reagent-antigen pair, whereby the formation of the reagent-antigen pair elicits a host immune response.

11 26. A method of designing new therapeutic agents comprising selecting a soluble antigen; and selecting a binding agent that specifically binds to said antigen to form a complex, a portion of said complex including an epitope that is exposed when in the complex but not exposed when not in a complex; and whereby said complex generates an immune response *in vivo*.

16 27. A method of treatment comprising administering a conjugate comprising a photosensitizer bound to a binding agent, and activating the photosensitizer by exposing the photosensitizer to light of a predetermined wavelength.

1 28. The method of claim 27 wherein the photosensitizer is a perylenequinone.

29. The method of claim 28 wherein the perylenequinone is a hypocrellin B derivative.

6 30. A method of stimulating the production of antibodies that bind to an epitope on a soluble antigen comprising:

administering to a host a binding agent that binds to the soluble antigen;

forming a complex between the binding agent and the soluble antigen, wherein the formation of the complex exposes an epitope that is unexposed when the binding agent is not complexed to the antigen;

11 and allowing the host to generate an antibody that binds to the exposed epitope.

31. The method of claim 30 wherein the structure of the antigen is complementary to the structure of the antibody that binds to the exposed epitope.

16 32. The method of claim 1 wherein the binding agent increases the immunogenicity of the antigen.

33. The method of claim 1 wherein the binding agent decreases the immunogenicity of the antigen.

1 34. The method of claim 33 wherein the antigen is associated with anti-inflammation.

 35. The method of claim 34 wherein the antigen is associated with rheumatoid arthritis.

6 36. The method of claim 1 wherein the complex increases the host immune response.

 37. The method of claim 1 wherein the complex decreases the host immune response.

 38. The method of claim 1 wherein the antigen is an antigen selected from the group consisting of CA 125; CA 15.3; CA 19.9; and prostate specific antigen.

11 39. The method of claim 7 wherein the antigen induces an immune response.

 40. The method of claim 7 wherein the binding agent/antigen complex induces an immune response.

16 41. A method of altering the immune response against an antigen comprising

1 obtaining a body fluid containing a pre-determined antigen from a patient;
combining the antigen with a composition comprising a binding agent, said
binding agent induces the production of an anti-idiotypic antibody;
permitting said binding agent to specifically bind to the antigen to form a
binding agent/antigen complex;

6 administering a composition containing the binding agent/antigen complex
to the patient, said complex being capable of altering the immune response against
the antigen.

42. A composition for inducing an immune response comprising a
composition comprising a binding agent that binds to a soluble antigen to form a
complex, said complex is capable of inducing a beneficial immune response.

43. The composition of claim 42 wherein the immune response is a cellular
and humoral response.

44. The composition of claim 42 wherein the immune response is a cellular
response.

16 45. The composition of claim 42 wherein the immune response is a humoral
response.

46. The composition of claim 42 wherein said binding agent includes a
binding agent selected from the group consisting of one member of an immunologic

1 pair; an antibody; a monoclonal antibody; an antibody fragment; a single chain antibody; a peptide; and a protein.

47. The composition of claim 42 wherein said antigen is a soluble antigen.

6 48. The composition of claim 47 wherein said antigen is selected from the group consisting of cancer; tumor; drugs of abuse; multiple sclerosis; allergy; human immunodeficiency virus; bacterial infection; autoimmune diseases; human viruses; and asthma.

49. The composition of claim 48 wherein said antigen is selected from the group consisting of breast, ovarian, prostate, gastro-intestinal, and anti-inflammation antigens.

11 50. The composition of claim 42 wherein the antigen is multi-epitopic.

51. The composition of claim 42 wherein the complex changes the conformation of the binding agent, said complex having an accessible epitope accessible when the binding agent is complexed with the antigen.

16 52. The composition of claim 51 wherein the complex induces the production of an anti-anti-idiotypic antibody to the accessible epitope.

1 53. The composition of claim 52 wherein the anti-anti-idiotypic antibody is defined by blocking the binding of a second anti-anti-idiotypic antibody to an anti-idiotypic antibody that binds to the binding agent.

6 54. The composition of claim 49 wherein the antigen is an antigen selected from the group consisting of CA 15.3, CA 125, CA 19.9, and prostate specific antigen.

 55. The method of claim 1 further comprising determining that the soluble antigen is multi-epitopic prior to administering the composition.

11 56. The method of claim 24 further comprising determining that the tumor associated antigen is multi-epitopic prior to contacting the antigen with the composition.

 57. The method of claim 10 wherein the cellular response comprises a change in antigen presentation.

 58. The method of claim 1 wherein the immune response comprises complement-dependent cytotoxicity or ADCC

16 59. The method of claim 24 wherein the immune response comprises complement-dependent cytotoxicity or ADCC

1 60. The method of claim 11 wherein the humoral response increases the complement-dependent cytotoxicity of the binding agent.

61. A composition for altering immunogenicity comprising a modified antigen, said modified antigen comprising an antigen bound to a binding agent.

62. The composition of claim 61 wherein the antigen is soluble.

6 63. The composition of claim 61 wherein the antigen is multi-epitopic.

64. A composition for altering immunogenicity comprising a binding agent that stimulates the production of antigen-reactive antibodies wherein the production of said antibodies provides a beneficial therapeutic effect.

65 The method of claim 64 wherein the antigen-reactive antibodies are AB3 and AB3'.

66. A method of altering immunogenicity comprising administering a composition comprising a binding agent that induces the production of AB3 and AB3'; and

permitting said binding agent to specifically bind to a soluble antigen.

1 67. A method of using a binding agent comprising administering a
composition comprising a binding agent and allowing said binding agent to induce
the production of AB3 and AB3'.

6 68. The method of claim 1 wherein administering a composition comprising
a binding agent further comprises increasing antibody-dependent cell-mediated
cytotoxicity and complement-dependent cytotoxicity.

11 69. A method of stimulating the production of antibodies which bind to
an epitope on a soluble antigen comprising: administering a monoclonal antibody
that specifically binds to a soluble antigen in an amount sufficient to stimulate the
production of anti-anti-idiotypic antibodies that immunoreact with the antibody-
antigen complex, wherein the production of anti-anti-idiotypic antibodies provides a
beneficial effect.

16 70. A comprehensive method for killing cells comprising administering a
composition comprising an Ab1 antibody that induces the production of at least
one of the following: molecules associated with a cellular response, molecules
associated with a humoral response, Ab3, Ab3', ADCC, CDC, cytotoxic T
lymphocytes, natural killer cells, cytokines, and chemokines.

1

Abstract of the Invention

The invention is therapeutic methods and compositions that alter the immunogenicity of the host.

Abstract





Figure 1






Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14




Figure 15

3530501 3530501 3530501





Figure 16

Figure 17

Therapeutic Experiment in SCID/BG-huPBL



09152698-090298

E	E								
139	140								
F	L	T	P	K	K	L	Q	C	V
141	142	143	144	145	146	147	148	149	150
D	L	H	V	I	S	N	D	V	C
151	152	153	154	155	156	157	158	159	160
A	Q	V							
161	162	163							

Figure 18




Figure 20

BLEEDING, IMMUNIZATION AND INFLAMMATION SCHEDULE			
Day	Bleeding	Immunization	Induction of inflammation
1	1 st	1 st	none
9	2 nd	2 nd	none
15	3 ^d	3 ^d	none
22	4 th	4 th	none
34	5 th	5 th	none
39	6 th		1 st

Bleeding was always done before immunization.








Figure 19